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ABSTRACT 
Development of a Prolyl Endopeptidase Expression System in Lactobacillus reuteri to 
Reduce the Manifestation of Celiac Disease 
Kara Lynn Jew 
 
Celiac Disease (CD) is an autoimmune disorder that emerges due to the ingestion of gluten, 
a protein found in a variety of common grains such as wheat, rye, and barley. 
Approximately 1 in 100 individuals in the US suffer from CD, making it the most 
commonly diagnosed gastrointestinal disorder (Ciclitira et. al., 2005). These proline-rich 
gluten peptides are resistant to proteolysis and accumulate in the duodenum of the small 
intestine. Once in the duodenum, these peptides illicit an autoimmune response resulting 
in villous atrophy. Current treatment for CD requires a rigorous adherence to a gluten-free 
diet. Nevertheless, gluten-containing grains are ubiquitous in the western diet, so accidental 
exposure to gluten remains as a persistent threat.  
 
The approach of this project centers on genetically engineering a strain Lactobacillus 
reuteri to secrete a Myxococcus xanthus prolyl endopeptidase (PEP), an enzyme that 
hydrolyzes a peptide bond adjacent to an internal proline residue. The data from this study 
revealed that recombinant M. xanthus PEP purified from E. coli was effective in degrading 
Suc-Ala-Pro-pNA, a chromogenic substrate containing an internal proline residue. When 
introduced into a L. reuteri expression vector, mutations accumulated in the vector over the 
course of 5 days. These data suggested that toxicity was possibly associated with M. 
xanthus PEP and the amyl signal peptide.  
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1. 0 Celiac Disease Background 
1.1 What is Celiac Disease? 
Celiac Disease (CD) is an autoimmune disease that is triggered by gluten, a protein found 
in a variety of common grains such as wheat, rye, and barley. The duodenum, the proximal 
portion of the small intestine, is the primary site affected by CD, but in some cases it may 
extend to the ileum (Ruben et al., 1962). When those with CD are exposed to gluten they 
can experience abdominal pain, diarrhea, and an inflammatory cutaneous disease resulting 
in lesions, rashes, and blisters on the skin known as dermatitis herpetiformis (Caproni et 
al., 2009). More severe symptoms lead to the destruction of the small intestine villi, finger-
like projections that allow for the absorption of nutrients. These symptoms include an 
elongation of the grooves located between villi (crypt hyperplasia) and the chronic 
inflammation of the cells lining the small intestine and destruction of villi (villous atrophy). 
The Crypts of Lieberkuhn are lined with young intraepithelial cells and are the source of 
intraepithelial stem cells of the small intestine. Thus, deepening of the Crypts of 
Lieberkuhn due to crypt hyperplasia indicates an increase in the production of 
intraepithelial cells. The reduction of the intestinal surface area due to villous atrophy may 
lead to the malabsorption of nutrients. The prevalence of CD is approximately 1 in 100 
among the Caucasian population, making it the most commonly diagnosed chronic 
gastrointestinal disorder in the United States (Ciclitira et. al., 2005 and García-Manzanares 
and Lucendo, 2011). However, the prevalence of CD increases to 7.5% for a first-degree 
relative of an individual with CD (Singh et al. 2015). 
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1.2 The Role of Gluten in CD 
Gluten is a proline- and glutamine-rich protein that can be segregated into two general 
classifications: glutenins and gliadins. Glutenin is the alcohol-insoluble fraction, which 
contributes to dough elasticity. Gliadin, the alcohol-soluble peptide, contains high levels 
of proline and glutamine residues as well as the dominant epitopes involved in inducing 
the immune response. High levels of proline residues allow gluten peptides to form 
proteolytic resistant structures that are not easily degraded by gastric, pancreatic, and brush 
border enzymes found in the human gastrointestinal tract (Kagnoff 2005). Because the 
structures are resistant to digestion, proline-rich peptides accumulate in the gastrointestinal 
tract, and the immunogenic epitopes of gluten are preserved. In particular, there are two 
major categories of immunogenic epitopes derived from α-gliadin: 
LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (33-mer) and PGQQQPFPPQQPY 
(p31-p43) (Ozuna et al. 2015). The main immunogenic epitope, 33-mer, is extremely stable 
and instigates an immune response in virtually all CD patients tested (Shan et al. 2002). As 
shown in Figure 1-1, the 33-mer contains six overlapping epitopes that have been shown 
to stimulate three different HLA-DQ2-restricted T cell clones from CD patients (Arentz-
Hansen et al. 2000). The p31-p43 peptide has been shown to stimulate the expression of 
MICA, a molecule associated with cytotoxicity in intestinal epithelial cells (IECs) (Hüe et 
al. 2004).  
 
 
 
 3 
 
 
   
 
 
Glutamine residues found within the immunogenic gluten epitopes serve as targets for 
tissue transglutaminase (tTG), an endogenous enzyme involved in the autoimmune 
response of CD. This enzyme is ubiquitously expressed throughout the intracellular and 
extracellular environments of many organs, and it targets glutamine residues in a QXP 
consensus sequence that will either be transamidated (cross-linked) or deamidated (Dørum 
et al., 2010). The enzyme primarily catalyzes the irreversible transfer of an acyl group from 
a glutamine residue to a lysine residue thereby forming an isopeptide bond (Lai et al., 
2017). This bond may form between glutamine and lysine residues of the same protein or 
two different proteins. Under acidic conditions tTG deamidates glutamine residues, an 
uncharged and polar amino acid, to glutamic acid, a negatively charged amino acid (Di 
Sabatino et al., 2011). Due to deamidation, gluten develops a stronger binding affinity to 
the major histocompatibility complex class II (MHC II) molecules that present antigens to 
pivotal cells of the immune response. The interaction between these gliadin peptides and 
tTG contributes to the hallmark of CD: anti-tTG antibodies. However, before gluten can 
invoke the immune and autoimmune responses, the peptides must first cross the intestinal 
epithelial layer into the lamina propria of the intestinal mucosa.  
Figure 1-1. The six DQ2-specific Epitopes (DQ2-α-I, DQ2-α-II, and DQ2-
α-III) Located in the 33-mer. 
 
DQ2-α-I: PFPQPQLPY 
DQ2-α-II: PQPQLPYPQ 
DQ2-α-III: PYPQPQLPY 
LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF  
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Under normal conditions macromolecules are inhibited from crossing the intestinal 
epithelial layer via tight junctions. In CD, the interactions between gliadin, CXCR3 
chemokine receptors, adaptor protein MyD88, and zonulin influence the integrity of the 
small intestine tight junctions and allow the passage of gluten from the intestinal lumen 
into the lamina propria. CXCR3 is a G-protein-coupled receptor responsible for binding 
CXC chemokines. These receptors are normally found on lymphocytes, smooth muscle, 
and epithelial cells, but are overexpressed on the luminal side of IECs in CD (Van 
Raemdonck et al. 2015; Fasano 2011). Gliadin binds CXCR3 receptors and stimulates the 
recruitment of the adaptor protein MyD88, which is essential in the signal transduction 
pathways that culminate in the activation of cytokines and the release of zonulin into the 
intestine (Thomas et al. 2006; Yu et al. 2006; Lammers et al. 2008). Zonulin is a protein 
released from IECs after exposure to enteric bacteria and gluten that regulates intercellular 
tight junctions (Wang 2000; Asmar et al. 2002; Thomas et al. 2006). It has been shown that 
in the presence of zonulin tight junction permeability increases due to protein kinase C-
dependent phosphorylation and displacement of zonula occluden-1 (ZO-1), a scaffold 
protein that couples integral plasma membrane proteins to other tight junction proteins and 
the cytoskeleton. Thus, it has been hypothesized that the gluten peptides cross into the 
intestinal mucosa when the tight junctions of the intestine are weakened due to the release 
of zonulin. Upon entry into the lamina propria of the intestinal mucosa, gluten peptides 
will initiate the immune responses.  
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1.3 The Immune Responses Involved in CD 
Villous atrophy in CD is induced by both the innate and adaptive immune systems through 
the NKG2 family of natural killer (NK) cell receptors and non-classical MHC I chain-
related molecule A (MICA). These receptors are expressed on both NK cells and a subset 
of cytotoxic T lymphocytes (CTLs). NK cells are not antigen-specific but are programmed 
to kill cells that have been compromised by a virus whereas CTLs target cells that present 
a specific antigen. Two types of surface NKG2 receptors may be expressed on NK cells 
and CTLs: an inhibiting (CD94/NKG2A) and activating (NKG2D) receptor. Under normal 
conditions, classical MHC I proteins, expressed on the surface of all nucleated cells, 
present self-antigens that are recognized by the inhibitory CD94/NKG2A receptor. MICA 
is an inducibly expressed ligand that acts as a cellular distress signal to stimulate 
cytotoxicity, cytokine secretion, and serves as an activating ligand for the activating 
NK2GD receptor (Baranwal and Mehra 2017; Bauer et al., 2002; Hüe et al., 2004). 
Inhibition signals produced from the engagement between the CD94/NKG2A receptor and 
MHC I override activation signals from the NKG2D receptor and MICA interaction. In 
cells where MHC I expression is greatly reduced (often a consequence of virally infected 
cells) the inhibition signals are not produced. The unimpeded activation signals lead to the 
destruction of the compromised cells through NK cell-mediated cytotoxicity or provide a 
costimulatory signal that enhances T cell receptor (TCR)-dependent cytolysis (Groh et al. 
2001). Thus, altered expression of MICA and the NKG2 receptors is vital to the 
development of villous atrophy in CD. 
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Expression of the NKG2 receptors and MICA is influenced by IL-15, a stress and 
inflammation induced cytokine critical in the activation of T and NK cells. In CD, the p31-
49 peptide of gliadin has been shown to upregulate surface expression of IL-15 on IECs as 
well as antigen presenting cells (APCs) in the lamina propia (Maiuri et al., 2003 and 
Bernardo et al., 2016). Overproduction of IL-15 leads to increased expression of NK2GD 
receptors on CTLs, and the presence of gliadin (α-gliadin and the p31-49 peptide) promotes 
the overexpression of MICA on IECs (Jabri et al. 2002; Roberts et al. 2001; Hüe et al. 
2004). The engagement between NK2GD and MICA acts as a costimulatory signal for 
TCR activation to stimulate cytolytic activity, and IL-15 lowers the activation threshold of 
the TCR (Groh et al. 2001; Roberts et al. 2001). Altogether, cytolysis of IECs is dependent 
on both NKG2D and the TCR, but efficient damage can take place at low self-antigen 
concentrations or low binding affinity for the self-antigen (Liu et al. 2013). Therefore, 
damage is more pervasive in a given area but restricted to IECs that express both IL-15 and 
MICA (Abadie and Jabri 2014). In more severe forms of CD, such as refractory CD 
(symptoms persist despite treatment with a gluten-free diet), cytolysis of IECs is 
independent of TCR activation and is solely mediated by NKG2D (Hüe et al. 2004). Thus, 
IECs are destroyed through cytotoxic-mediated killing ultimately leading to the 
development of crypt hyperplasia and villous atrophy. These responses explain how gluten 
is involved in adaptive and innate immunity of CD; however, the autoimmune response 
has not been addressed.  
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1.4 Autoimmune Responses Involved in CD 
Environmental factors, genetic predispositions, and, most importantly, the failure of 
immune tolerance contribute to the development of autoimmunity. Two mechanisms, 
central and peripheral tolerance, regulate B cells to prevent these cells from becoming auto-
reactive. Central tolerance takes place in the primary lymphoid organs during lymphocyte 
repertoire development when B cells are equipped with receptors to identify specific 
antigens. Immature B cells that bind to self-antigens with high affinity undergo apoptosis, 
or genes are rearranged so the receptor no longer binds the self-antigen. Peripheral 
tolerance occurs in the secondary lymphoid organs and acts as a back-up plan for auto-
reactive cells that escape central tolerance. This form of immune tolerance is necessary 
when the self-antigen is solely found outside primary lymphoid organs or when the cells 
encounter a soluble form of the self-antigen. Recognition of a self-antigen in the absence 
of a co-stimulatory signal from a helper T cell results in the B cell becoming anergic. The 
B cell can no longer to respond to that antigen even if presented under proper conditions. 
When either central or peripheral tolerance fails, B cells are incapable of distinguishing 
between self and non-self proteins, thus an immune response can be triggered by a self-
protein. However, unlike most autoimmune diseases, a foreign antigen (gliadin) and self-
protein (tTG) are both responsible for initiating autoimmune responses of CD.   
 
Gliadin is a preferred substrate for tTG to act upon; approximately 36% of glutamine 
residues in gliadin are accessible to tTG modification (Di Sabatino et al. 2012). The 
deamidation activity of tTG is critical for the presentation of gliadin peptides by MHC II 
molecules. There is a strong genetic association between CD and the MHC II HLA-DQ 
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locus. Approximately 90% of CD individuals either have the MHC II HLA-DQ2.5 or DQ8 
alleles (Sollid & Thornsby, 1993 and Lucendo, 2011). Moreover, MHC II HLA-DQ2.5 and 
DQ8 have a binding preference for negatively charged epitopes (Molberg et al., 1998 and 
Dørum et al., 2010). Therefore, the conversion of uncharged, polar glutamine residues to 
negatively charged glutamic acid residues bolsters the avidity of MHC II HLA-DQ2.5 or 
DQ8 for gliadin epitopes. Additionally, the preference for the deamidated immunogenic 
peptides of gliadin is strong enough to displace antigens that may already be presented by 
these MHC II HLA-DQ molecules (Xia, Sollid, and Khosla 2005). Furthermore, tTG can 
cross-link itself to immunodominant peptides of gliadin through transamidation (Dieterich 
et al., 2006). Auto-reactive self-tTG B cells bind tTG that has been cross-linked with 
gliadin, and the tTG-gliadin complex is endocytosed, degraded, processed, and the antigens 
are presented via the MHC II HLA-DQ heterodimer (Di Sabatino et al., 2012). Even though 
both gliadin peptides and tTG were taken up by the auto-reactive tTG-specific B cell, MHC 
II DQ2.5 and DQ8 preferentially present the immunogenic peptides of deamidated gliadin 
(Di Sabatino et al. 2012). Gliadin-specific TH2 cells then recognize the gliadin fragments 
presented by auto-reactive tTG-specific B cells and stimulate the B cells to produce anti-
tTG antibodies. It is significant to note that the activation of auto-reactive tTG-specific B 
cells does not require stimulation from auto-reactive tTG-specific T cells. Thus, the 
formation of the cross-linked tTG-gliadin complex and the modification of the negatively 
charged gliadin peptide are essential for the production of anti-tTG antibodies from auto-
reactive tTG B cells. Although these anti-tTG antibodies are characteristic of CD, the exact 
function of the antibodies in CD pathology remains unclear. 
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1.5 Diagnosis of CD 
The presence of MHC II HLA-DQ2.5 or DQ8 alleles, anti-tTG IgA antibodies, and villous 
atrophy are distinguishing features of CD. If there is a risk of acquiring CD individuals will 
undergo preliminary genetic and serological tests to screen for the disorder. Although 20-
30% of the general population carries the MHC II HLA-DQ2.5 or DQ8 alleles, the presence 
of these alleles may increase the risk of developing CD (Bodis, Toth, and Schwarting 
2018). Individuals that were homozygous for HLA-DQ2.5 had the highest risk for 
developing CD; however, the absence of the MHC II HLA-DQ2.5 or DQ8 alleles was a 
strong indicator that an individual would not develop CD (Sollid and Lie 2005). Moreover, 
other genetic factors may contribute to the development of CD. Studies conducted on twins 
and the occurrence of CD have indicated a ~0.80 concordance rate (the probability a twin 
is affected provided that the co-twin is affected) compared to a concordance rate of <0.20 
in dizygotic twins (Nistico 2006; Greco 2002). Thus, the presence of the MHC II HLA-
DQ2.5 or DQ8 alleles is necessary for development of CD, but these alleles are not 
sufficient to confirm the risk of developing CD. Prior to the serological test, the patient is 
subjected to a gluten challenge (GC) where the individual will include gluten in their diet 
to promote the immune and autoimmune responses associated with CD. A study has shown 
that a 14-day GC with ≥ 3 grams of gluten consumed per day was sufficient to induce the 
serological hallmarks of CD (Leffler et al. 2013). Following the GC, a serological test is 
performed to detect the presence of anti-tTG IgA antibodies, an indicator that the 
autoimmune response of CD has been triggered. Approximately 98% of adult patients with 
CD test positive for tTG-IgA while on a gluten-containing diet, and 98% of individuals 
without CD test negative for this antibody (Lebwohl et al. 2012). Genetic and serological 
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tests may eliminate the prospect of CD or narrow down the array of potential disorders; 
however, they cannot confirm if an individual has CD. If individuals test positive for these 
genetic and serological tests, then the diagnosis must be confirmed with a duodenal biopsy 
to detect villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis (increased 
production of intraepithelial lymphocytes) consistent with CD.  
 
1.6 Current Treatments for CD 
No cure for CD has been discovered, and the only known method to manage the disorder 
is a strict and lifelong adherence to a gluten-free diet (GFD): elimination of wheat, rye, 
barley, and any food products that were derived from those grains. Most individuals 
experience a substantial improvement in symptoms after maintaining a GFD. However, 
symptoms may persist for others due to accidental gluten consumption, because those 
gluten-containing grains are thoroughly abundant in the western diet. For example, there 
is no current law that mandates manufacturers disclose if medications contain gluten. 
Moreover, sensitivity to gluten and the degree of the immune response may differ amongst 
individuals with CD. Those with extreme gluten sensitivity may suffer a severe immune 
response to a trace amount of gluten, therefore, maintaining an absolute GFD is 
challenging. In addition, individuals are often dissatisfied with a GFD due to the high cost 
of food and restrictive nature of this lifestyle, so interest in alternative strategies to manage 
CD is growing (Aziz et al., 2010). Long-term consequences of ingesting gluten may arise 
in the future even if the immediate symptoms of CD subside. A minority of individuals 
may develop more severe disorders such as ulcerative jejunitis (characterized by villous 
atrophy and chronic ulcers in the small intestine), small bowel adenocarcinoma (a type of 
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cancer that emerges in mucus-secreting glands), and enteropathy-associated T-cell 
lymphomas (EATL) due to unmanaged CD (Elsing et al., 2005; Basha et al., 2014; and Al-
Bawardy et al. 2017). For individuals with CD, the estimated relative risk in developing 
small bowel adenocarcinoma and EATL increases 80-fold and 30-fold, respectively 
(Meijer et al. 2004). Thus, a therapy to defend the small intestine from trace amounts of 
gluten would be beneficial for individuals with CD. 
 
Prolyl endopeptidases (PEPs) and prolyl aminopeptidases (PAPs) are proteases with the 
unique ability to hydrolyze peptide bonds adjacent to an internal and a terminal proline 
residue, respectively. These peptidases may be used to break down the immunogenic 
epitopes of gluten, thereby assuaging the autoimmune response of CD. Previous studies 
have shown the use of PEPs as a potential treatment for CD (Shan et al. 2004); however, 
the enzyme therapy requires that an individual anticipates consuming gluten-containing 
foods. This would not protect an individual from accidental gluten consumption. Moreover, 
orally administered enzymes must pass through the low pH of the stomach and proteolytic 
enzymes: pepsin, trypsin, and chymotrypsin. Probiotics such as Lactic Acid Bacteria 
(LAB) are acid-tolerant, therefore, some probiotics are capable of surviving the acidic 
environment of the stomach to colonize the gut. Thus, the use of a probiotic to deliver the 
enzyme to the site affected by CD may provide an alternate defensive strategy against CD.  
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1.7 Study Goal  
The goal of this study was to develop a probiotic expression system that allowed for the 
production PAPs and PEPs capable of cleaving proline-rich immunogenic peptides. A 
pET30 expression system in E. coli strain BL21(DE3) was employed to evaluate the 
expression and cleavage activities of the Myxococcus xanthus PEP (MxPEP), Aspergillus 
niger PEP (AnPEP), Lactobacillus acidophilus PAP (LaPAP), Lactobacillus reuteri PAP 
(LrPAP), and patented Aspergillus niger PEP (AnPat PEP). The expression of these 
proteins was analyzed through western blot, and the activity of the enzymes was evaluated 
through a chromogenic substrate assay. The enzyme with the most efficient activity was 
incorporated into a L. reuteri expression cassette. Expression of the enzyme was assessed 
through SDS-PAGE and western blot.  
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2.0 The Assessment of the Cleavage Activity of Prolyl Aminopeptidases and Prolyl 
Endopeptidases on Proline-containing Substrates 
2.1 Introduction 
2.1.1 Serine Proteases 
Serine proteases are ubiquitously found in eukaryotes, prokaryotes, archaea as well as 
viruses. Approximately one third of known proteolytic enzymes are serine proteases which 
are characterized by a catalytic triad of asparagine, histidine, and serine residues. The name 
is derived from the nucleophilic serine residue in the active site which donates electrons to 
the carbonyl of a peptide to form an acyl-enzyme intermediate (Hedstrom 2002). Because 
of their naturally destructive nature, these enzymes are generally stored as zymogens (an 
inactive form of the protein) and are activated by location-specific cleavage. In humans, 
the pancreas secretes the zymogen trypsinogen which localizes to the duodenum where it 
is cleaved by enteropeptidases to form active trypsin. Trypsin along with chymotrypsin and 
elastase promote the digestion of proteins in the GI tract; however, these serine proteases 
remain relatively ineffective against gluten. For example, trypsin acts upon the C-terminus 
of arginine and lysine residues, but these residues are scarce throughout gliadin peptides 
(Ferranti et al. 2007). Furthermore, proline residues located at the carboxyl end of the 
aforementioned residues interfere with the proteolytic activity of trypsin. Alternative serine 
proteases such as prolyl aminopeptidase (PAP) and prolyl endopeptidase (PEP) are capable 
of hydrolyzing proline-containing peptides, thus these enzymes may be a valuable asset for 
gluten hydrolysis. 
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2.1.2 Prolyl Endopeptidases and Prolyl Aminopeptidases 
PAPs cleave at the N-terminus of a proline residue whereas PEPs cleave internal peptide 
bonds at the C-terminus of an internal proline residue, and these proteases target smaller 
peptides (~30 amino acids) as their substrates. Because these are features of the 
immunogenic 33-mer of gliadin, PAPs and PEPs may be a promising therapeutic for CD. 
Previous studies have successfully isolated and characterized PEPs and PAPs from fungi 
(Aspergillus niger) and bacteria (Myxococcus xanthus, Flavobacterium meningosepticum, 
and Sphingomonas capsulate). The A. niger PEP (AnPEP) displayed enzymatic activity 
between pH 2-8, but was most effective at hydrolyzing gluten at pH 4 (Montserrat et al. 
2015). Another study further assessed the immunoreactivity of AnPEP hydrolyzed wheat 
flour (AnPEP HWF) on the development of an immune response in Caco-2 cells (Mohan 
Kumar et al. 2019). The study reported a reduction in the immune response when these 
Caco-2 cells did not exhibit an increase in zonulin. This study reported that Caco-2 cells 
stimulated with AnPEP HWF did not exhibit a significant increase in zonulin compared to 
that of cells exposed to gliadin. Moreover, the spleenocytes of gluten-sensitive mice treated 
with AnPEP hydrolyzed wheat flour did not yield a marked increase in IL-15 compared to 
mice challenged with gluten. In a comparative analysis of PEPs derived from M. xanthus, 
F. meningosepticum, and S. capsulate, all PEPs exhibited optimal catalytic activity at pH 
7; however, the M. xanthus PEP displayed the highest affinity for the chromogenic 
substrate, Suc-Ala-Pro-pNA (Shan et al. 2004). Furthermore, it has been reported that the 
F. meningosepticum PEP was effective at reducing immunogenicity associated with gliadin 
epitopes (Marti et al. 2004) 
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2.1.3 Study Goal 
The purpose of this study was to assess the enzymatic activity of a PEP from M. xanthus 
and PAPs from A. niger, Lactobacillus acidophilus, and Lactobacillus. reuteri. These 
genes were introduced into the inducible pET30 expression vectors and transformed into 
E. coli BL21(DE3). Recombinant protein expression was evaluated by SDS-PAGE and 
western blot, and enzyme activity was assessed through chromogenic substrate assays with 
Suc-Ala-Pro-pNA or H-Pro-pNA. The PEP or PAP that exhibited the highest enzymatic 
activity was used in the construction of L. reuteri expression vectors.  
 
2.2 Materials and Methods 
2.2.1 Strains and growth conditions 
E. coli strains TOP10 , MC1061, and BL21(DE3) were utilized in this study. TOP10 was 
used to harbor pCR2.1-derived vectors. Newly constructed pET30 expression vectors were 
first cloned into MC1061, and BL21(DE3) was used to express recombinant proteins from 
pET30-based expression vectors. Cultures were grown at 37˚C under aerobic conditions in 
Luria Bertani (LB) broth or plates. Either ampicillin 100 µg/ml (Amp 100) or kanamycin 
30 µg/ml (Kan 30) were added to the media for strains containing pCR2.1-derived vectors.  
Cultures containing pET30 expression vectors were grown in media supplemented with 
Kan 30.  
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2.2.2 Molecular techniques 
Polymerase chain reaction (PCR) was performed using Taq or Phusion DNA polymerase 
in 20 µl volumes. All reactions contained a final primer concentration of 0.1 µM and 
approximately 0.2 ng of template DNA. For reactions using GoTaq 1X Master Mix 
(Promega, Madison, WI, USA), DNA was initially denatured at 95˚C for 2 minutes. Each 
reaction was then carried out for 30 cycles of 30 seconds at 95˚C, 30 seconds at 55˚C, and 
1 minute per kb of expected product at 72˚C. Following the 30 cycles, a final 5-minute 
extension at 72˚C completed the reaction. When using Phusion Flash High-Fidelity PCR 
1X Master Mix (Thermo Scientific, Rockford, IL, USA), DNA was initially denatured for 
10 seconds at 98˚C. Subsequently, reactions were executed for 30 cycles of 1 second at 
98˚C, 30 seconds at 55˚C, and 15 seconds per kb of expected product at 72˚C. The reaction 
ended with a final 5-minute extension step at 72˚C and incubation at 4˚C.  
Colony PCR was used to evaluate 11-22 CFUs to determine if the colonies contained the 
recombinant plasmid of interest. Briefly, colonies were suspended in separate aliquots from 
a PCR master mix (primers and 1X GoTaq master mix) and spot inoculated on LB Kan 30 
from each PCR reaction mixture. The primer pairs contained in the PCR master mix were 
chosen to identify the presence and orientation of the insert; one primer was specific to the 
insert and another annealed solely to the vector. For example, a forward primer specific to 
the 5’ end of the insert and a reverse primer that annealed to the vector downstream from 
the insert, or a forward primer within the vector upstream from the insert and a reverse 
primer specific to the 3’ end of the insert.  
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All restriction digests using AscI, BamHI, EcoRI, and SalI (Thermo Scientific, Rockford, 
IL, USA) were carried out in 20 µl reaction volumes that contained 1X FastDigest Buffer 
and 300 – 800 ng of DNA. Restriction enzymes were incubated at 37˚C for 1 hour and heat 
inactivated at 80˚C for 5 minutes. Following digests, vectors were dephosphorylated with 
1X OPTIZYME Alkaline Phosphatase (Thermo Scientific, Rockford, IL, USA) to prevent 
self-ligation. Reactions contained 10X OPTIZYME AP buffer and 600-800 ng of linear 
DNA. Dephosphorylation reactions were performed at 37˚C for 1 hour and heat inactivated 
75˚C for 5 minutes.  
 
Ligations were performed with T4 DNA Ligase (Thermo Scientific, Rockford, IL, USA) 
in a 10 µl reaction mixture containing a 3:1 insert:vector molar ratio (300 ng vector) and 
1X T4 DNA Ligase Buffer. The reactions were ligated at 22˚C for 60 minutes and heat 
inactivated at 70˚C for 5 minutes. Ligated vectors were transformed into E. coli strains 
MC1061 and BL21(DE3).  
 
2.2.3 Optimizing prolyl endopeptidase (PEP) and prolyl aminopeptidase (PAP) sequences 
via gene synthesis  
E. coli and L. reuteri codon usage tables (http://www.kazusa.or.jp/codon/) were used in a 
relative adaptiveness analysis (http://gcua.schoedl.de/) to optimize the M. xanthus PEP and 
A. niger patented PAP sequences for expression in E. coli and L. reuteri. For this analysis, 
codon usage tables for E. coli and L. reuteri were compared with the M. xanthus PEP and 
A. niger patented PAP sequences. In the relative adaptiveness analysis, codon frequencies 
were converted to relative adaptiveness values; the most frequent codon for a particular 
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amino acid was set to 100% relative adaptiveness, and the remaining codons for that amino 
acid were scaled as follows:  
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑎𝑑𝑝𝑎𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑣𝑎𝑙𝑢𝑒 = 𝐶𝑜𝑑𝑜𝑛 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 (
100
𝐻𝑖𝑔ℎ𝑒𝑠𝑡 𝑐𝑜𝑑𝑜𝑛 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦
) 
 
The relative adaptiveness analysis provided the capability to compare codon frequencies 
between different amino acids. Both the M. xanthus PEP and A. niger patented PAP 
sequences were rewritten to contain the codons that yielded the highest relative 
adaptiveness values between E. coli and L. reuteri. The analyses were performed by 
Graphical Codon Usage Analyser. The optimized M. xanthus and A. niger sequences were 
synthesized by Life Technologies (Carlsbad, CA, USA).  
 
2.2.4 Optimizing L. reuteri PAP sequence via PCR stitching  
For use in this work and a related study, the L. reuteri PAP sequence was optimized for 
expression in Saccharomyces cerevisiae, E. coli, and L. reuteri by site-specific mutagenesis 
through PCR stitching (Figure 2-1 and Figure 2-2.). The Reuteri-PAP-EcoRI-F and 
Reuteri-PAP-RsaI-mut-R primers were used to amplify piece A. These primers introduced 
a new RsaI site into the sequence and mutated two CGG codons to CGT. In addition, 
Reuteri-PAP-EcoRI-F and Reuteri-PAP-Arg-GFP-R were used to create piece B that 
mutated one CGG codon to CGT and incorporated a BglII restriction site and a 3’ end of 
GFP. Piece B was digested with RsaI and treated with terminal deoxynucleotidyl 
transferase (Promega, Madison, WI, USA) to prevent its amplification. Pieces A and B 
were PCR stitched with Reuteri-PAP-EcoRI-F and GFP-EcoRI-R to generate piece AB, 
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the round 1 mutant (Rd1 mut). This amplicon was digested with BglII and EcoRI ligated 
with pCR 2.1 that was digested with EcoRI and BamHI. Using pCR 2.1 Rd1 mut as a 
template, primer pairs Reuteri-PAP-EcoRI-F/Lr-PAP-SalI-mut-R and Lr-PAP-SalI-mut-
F/Reuteri-PAP-Arg-GFP-R generated pieces C and D, respectively. These pieces were 
PCR stitched with Reuteri-PAP-EcoRI-F and GFP-EcoRI-R to create piece CD, the round 
2 mutant (Rd 2 mut). Rd2 mut was digested with EcoRI and BglII and inserted into the 
THA expression cassette in pRS416. The expression cassette contained the triosephophate 
isomerase promoter (T), histidine tag (H), and alcohol dehydrogenase terminator (A). 
Table 2-1 contains the primers used to optimize the L. reuteri PAP sequence. 
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Figure 2-1. Construction of pCR 2.1 Rd1 Mut. Two CGG codons were mutated to 
CGT and an RsaI site was introduced into the 5’ end of LrPAP (A). LrPAP was 
amplified to contain at the 3’ end of the sequence (B). The resulting pieces were PCR 
stitched to generate RdI mut that contained 3 mutated arginine codons (AB).   
LrPAP 
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Figure 2-2. Construction of Final Optimized L. reuteri PAP (Rd2 Mut). A 5’ portion 
of RdI mut was amplified to incorporate a SalI site and mutate the final CGG codon to 
CGT (C). The 3’ end of RdI mut was amplified to mutate the final CGG codon to CGT 
and add the 5’ end of GFP as well as a SalI site (D). Both pieces were PCR stitched to 
generate Rd2 mut with 4 mutated arginine codons (CD).  
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2.2.5 Construction of pET30 vectors 
The M. xanthus PEP, L. acidophilus PAP, L. reuteri PAP, and A. niger patented PAP 
(Kang, Yu, and Xu 2013) sequences were cloned into pET30 using an AscI restriction site 
located upstream from a histidine tag. Table 2-2 contains the primers that were used in the 
construction of the pET30 expression vectors. 
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2.2.6 Transformation into E. coli strains TOP10, MC1061, and BL21(DE3) 
Three strains of E. coli, TOP10, MC1061, and BL21(DE3), were utilized for the 
transformations performed in this study. For transformations into E. coli TOP10, 2 µl of 
the vector was incubated with 40 µl of TOP10 at 42 ˚C for 30 seconds, and transformants 
were immediately incubated with 250 µl SOC recovery medium for 45 minutes at 37˚C. 
After recovery incubation, 100 µl of the cells were plated on LB Amp 100 and grown for 
18 hours at 37 ˚C. The newly constructed pCR 2.1 Rd1 mut was transformed into E. coli 
TOP10. 
 
Electrocompetent E. coli BL21(DE3) were prepared by diluting an overnight culture 1:100 
in 250 ml SOB. The culture was grown to OD600= 0.5 – 0.7 and centrifuged at 3,000xg for 
10 minutes at 4˚C. Cells were washed twice with 250 ml nanopure water and once with 
250 ml 10% glycerol. The supernatant was poured off and the pellet was resuspended in 
residual 10% glycerol. Electrocompetent cells were divided into 140 µl aliquots and flash 
frozen in liquid nitrogen and stored at -80˚C. All electroporations were performed with 40 
µl electrocompetent cells and 200-500 ng of DNA using the BTX Electro Cell Manipulator 
600 (Harvard Apparatus Inc; 2.45 kV, 129 Ω). Transformants were incubated at 37˚C for 
1 hour in 500 µl SOC recovery medium. After recovery incubation, 100 µl of cells were 
plated on LB Kan 30 agar and grown for 18 hours at 37˚C. All pET30-derived vectors were 
first transformed into MC1061 to obtain purified plasmid and subsequently electroporated 
into BL21(DE3) to evaluate expression of the proteins of interest. 
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2.2.7 Recombinant protein expression and purification 
BL21(DE3) E. coli cultures harboring pET30 expression vectors were grown overnight at 
37˚C in 3 ml LB Kan 30 broth. Overnight cultures were diluted 1:100 in 250 ml LB Kan 
30 broth, grown to OD600= 0.5 – 0.7, and induced for 18 hours with 0.1 mM IPTG at 22˚C. 
Following induction, cells were pelleted at 8,000xg for 4 minutes at 4˚C. Pellets were 
resuspended in 25 ml TKE (50 mM Tris pH 7.5, 2.5 mM KCl, and 0.5 mM EDTA) and 
sonicated for 30 seconds at power setting 5 (~14 RMS) and incubated on ice for 60 seconds 
for a total of 3 times. Sonicated samples were spiked with 125 µl of Triton X-100 (0.5% 
final concentration) and incubated for 15 minutes at room temperature. After the incubation 
period, samples were centrifuged at 10,000xg for 10 minutes at 4˚C to separate unbroken 
cells, cell debris, and insoluble proteins (pellet) from soluble proteins (lysate). 
Recombinant proteins containing a C-terminal histidine tag were purified with HisPurTM 
Ni-NTA resin (Thermo Scientific, Rockford, IL, USA). Resin was prepared by washing 
twice with 500 µl water and once with 500 µl TKE. Lysates were incubated on ice with 
~250 µl bed volume of Ni-NTA resin for 30 minutes. Ni-NTA bound proteins were 
separated from unbound proteins by centrifugation at 3,000xg for 5 minutes at 4˚C. Pellets 
were resuspended in 4 ml TKE, transferred to a polypropylene column, washed twice with 
5 ml TKE, and Ni-NTA bound proteins were eluted with 2 ml 100 mM imidazole. Eluates 
were transferred into 1 inch dialysis tubing with a molecular weight cutoff of 12 to 14 kDa 
(Carolina Biological Supply Company, Burlington, NC, USA). Samples were dialyzed in 
330 ml storage buffer (50 mM Tris-HCl, pH 8.2, 1 mM DTT, 0.1 mM EDTA, 0.1% Tween-
20, and 57% glycerol) for three days, and used storage buffer was replaced twice after 24 
hours.  
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2.2.8 SDS-PAGE and Western Blots 
Protein samples were prepared with a 4X SDS-PAGE sample buffer (250 mM Tris pH 6.8, 
8% SDS, 40% glycerol, 0.02% bromophenol blue, and 5% β-mercaptoethanol), boiled at 
99˚C for 3 minutes, and placed on ice. From each sample, 15 µl were electrophoresed for 
90 minutes at 100 V on a 12% polyacrylamide gel. Following electrophoresis, SDS-PAGE 
gels used to evaluate cell lysates and purified protein samples were then stained with 
GelCodeTM Blue Safe Protein Stain (Thermo Scientific, Rockford, IL, USA) for 60 minutes 
and destained overnight in water.  
 
SDS-PAGE gels used to identify proteins of interest were subsequently analyzed by 
western blot. Proteins electrophoresed on SDS-PAGE were immediately transferred to a 
nitrocellulose membrane using a submersible transfer (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA) at 150 mA for 30 minutes after electrophoresis.  Following the 
transfer, membranes were incubated with Ponceau S to visualize and mark the molecular 
weight standard bands. Membranes were blocked overnight in 3% fat-free milk powder 
dissolved in TBST (25 mM Tris, 0.15 M NaCl, and 0.05% Tween-20; pH 7.2) at 4˚C. The 
next day membranes were incubated in a hybridization oven with either 10 ml 1:2000 anti-
GFP-HRP or 1:5000 Ni-HRP for 45 minutes at 25.5˚C and subsequently washed 4 times 
with 5 ml TBST. Blots were incubated with 7 ml Supersignal West Pico Substrate Working 
Solution (Thermo Scientific, Rockford, IL, USA) to detect HRP activity. Western blots 
were visualized by chemiluminescent detection using the ChemiDoc XRS+ (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA).  
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2.2.9 Enzyme Activity Assay 
PEP and PAP enzyme activity was measured with the chromogenic substrates Succinyl-
Alanyl-Prolyl-p-nitroanilide (Suc-Ala-Pro-pNA) or H-Prolyl-p -nitroanilide (H-Pro-pNA) 
(Bachem, Torrance, CA, USA), respectively. Enzyme concentrations were quantified with 
a BCA protein assay (Thermo Scientific, Rockford, IL, USA). Reaction mixtures (200 µl) 
contained 100 mM potassium phosphate buffer pH 7.0, 0.1–2 mM chromogenic substrate, 
and 0.6 µM LaPAP, 0.3 µM purified LrPAP, or 0.015 µM MxPEP. Stocks of Suc-Ala-Pro-
pNA (dissolved in water) and H-Pro-pNA (dissolved in 20% methanol) were prepared at a 
concentration of 5 mM. The release of pNA was kinetically measured at a wavelength of 
410 nm using a SpectraMax Plus 384 microplate reader (Molecular Devices, Sunnyvale, 
CA, USA). Enzymatic assays with the PEP were performed for 10 minutes, and absorbance 
measurements were taken at 10-second intervals. Assays containing a PAP were carried 
out for 60 minutes with absorbance measurements taken every 30 seconds. All reactions 
were incubated at 37˚C.  
 
Because a vertical beam of light was used to measure the absorbance of pNA, the 
pathlength was dependent on the height of the reaction mixtures. The pathlength for a 200 
µl reaction mixture was determined by measuring the absorbance of p-nitrophenol (PNP). 
PNP was diluted from 2.06x10-6M – 4.12x10-5 M in 0.1M Na2CO3, and the absorbances 
were measured in triplicate at 400 nm. The pathlengths (b) were calculated according to 
Beer’s Law:  
𝐴 = 𝜀𝑃𝑁𝑃 𝑏𝑐 
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Where A is the absorbance of the PNP, HPNP is the molar absorptivity coefficient of PNP 
(1.7x10-4 M-1 cm-1), and c is the concentration of PNP. The average pathlength was used to 
adjust the molar absorptivity value of pNA (HpNA). 
 
Velocities of the reactions were used to calculate international units (IU), the amount of 
enzyme required to convert 1 µmole of substrate per minute, according the following 
formula:  
 
𝐼𝑈 =
(𝐴𝐵𝑆410 𝑛𝑚)(𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑚𝑖𝑥𝑡𝑢𝑟𝑒 𝑣𝑜𝑙𝑢𝑚𝑒, 𝑙)
(𝑚𝑖𝑛𝑢𝑡𝑒)(µ𝑀 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝜀𝑝𝑁𝐴 )
 
 
The kinetic data was analyzed through Michaelis-Menten and Lineweaver-Burk plots to 
determine the Vmax and Km values for each enzyme.  
 
2.3 Results 
2.3.1 Optimizing PAP and PEP sequences 
Because the genetic code has redundancies, certain amino acids are encoded by more than 
one codon. Since the PEP and PAP were obtained from different originating 
microorganisms, codon bias was an issue when incorporating the sequences into E. coli 
and L. reuteri. Table 2-1 shows the codons with the highest relative adaptiveness values 
between E. coli and L. reuteri. These codons were used to rewrite the patented A. niger 
PAP (AnPat PAP) and M. xanthus PEP (MxPEP) sequences that were synthesized by Life 
Technologies. See appendix for complete AnPat PAP and MxPEP sequences.  
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2.3.2 Optimizing L. reuteri PAP via PCR stitching 
For expression in S. cerevisiae (used in a related study), E. coli, and L. reuteri, four arginine 
codons were mutated from CGG to CGT in the L. reuteri PAP (LrPAP) sequence. Three 
of the four arginine codons in LrPAP WT were mutated via PCR stitching to create Rd1 
mut. To confirm successful mutation of the 3 arginine codons, piece A, piece B, Rd1 mut, 
and LrPAP WT were amplified with Lr-PEP-EI-F/GFP-EI-R, and the resulting amplicons 
were digested with RsaI (Figure 2-3). Amplification and subsequent digest patterns were 
not expected from piece A or B; however, the RsaI digest on the piece B PCR product 
resulted in a pattern similar to that of Rd1 mut (511 +253 bp). Digests on RdI mut and 
LrPAP WT (651 + 253 bp) yielded expected fragments. Although the 140 and 40 bp 
fragments were too small to detect on the agarose gel, the shift from the 651 bp band in 
LrPAP WT to the 511 bp fragment in Rd1 mut indicated the three arginine codons were 
successfully mutated. Rd1 mut was cloned into pCR2.1, and the resulting vector, pCR2.1 
Rd1 mut, transformed into E. coli TOP10.  
Alanine (A) GCT Glycine (G) GGT Proline (P) CCA 
Arginine (R) CGT Histidine (H) CAT Serine (S) TCA 
Asparagine (N) AAT Isoleucine (I) ATT Theronine (T) ACT 
Aspartic acid (D) GAT Leucine (L) TTA Tryptophan (W) TGG 
Cysteine (C) TGT Lysine (K) AAA Tyrosine (Y) TAT 
Glutamic Acid (E) GAA Methionine (M) ATG Valine (V) GTT 
Glutamine (Q) CAA Phenylalanine (F) TTT Stop TAA 
 
Table 2-3. Codons Used to Rewrite the AnPat PEP and MxPEP Sequences. 
These codons had the highest relative adaptiveness values between E. coli and L. 
reuteri.  
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Figure 2-3. RsaI Restriction Digest on Rd1 Mut and LrPAP WT. Digests were 
analyzed by 2% agarose gel.RdI mut (511 + 253 bp) and LrPAP WT (633 + 253 bp) 
yielded the expected band sizes. The band shift from 633 bp in LrPAP WT to 511 
bp in RdI mut demonstrate successful mutation of the 3 arginine codons.  
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Subsequently, pCR2.1 Rd1 mut was used as a template to generate Rd2 mut which 
contained all four mutated arginine codons. To confirm successful mutation of the final 
arginine codon, Rd1 mut, amplified with Lr-PAP-EI-F/Lr-GFP-Arg-R from pCR2.1 Rd1 
mut and the PCR stitched Rd2 mut amplicon were digested with SalI (Figure 2-4). The 
expected digest patterns were observed from Rd1 mut (503+437 bp) and Rd2 mut 
(437+372+135 bp). Although the 135 bp fragment was not seen from the digest on Rd2 
mut, the shift from the 503 bp fragment in Rd1 mut to the 372 bp band in Rd2 mut indicated 
that an additional SalI was incorporated and the arginine codon was mutated. Rd2 mut was 
the optimized version of LrPAP used to clone into pET30.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-4. SalI Restriction Digests on Rd1 Mut and Rd2 Mut. Digests were 
analyzed by 2% agarose gel. Both Rd1 mut (503+437 bp) and Rd2 mut (437+372+135 
bp) yielded expected band sizes which indicated the addition of a SalI restriction site 
and successful mutation of the fourth arginine codon in Rd2 mut.  
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2.3.3 Construction and transformation of pET30-derived expression vectors into E. coli 
BL21(DE3) 
The pET30 vectors containing the AnPat PAP, MxPEP, L. acidophilus PAP (LaPAP), and 
LrPAP were digested with AscI to determine if the vectors were transformed into E. coli 
BL21(DE3). With the exception of pET30 GFP, all AscI restriction digests on the pET30-
derived vectors yielded the expected band sizes (Figure 2-5). These pET30 vectors were 
successfully transformed into E. coli BL21(DE3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5. AscI Restriction Digests on pET30 AnPat PAP, LaPAP, LrPAP, 
MxPEP, and GFP. Digests were analyzed on a 1% agarose gel. The AscI digests 
resulted in the expected band sizes for pET30 AnPEP, pET30 AnPat PAP, pET30 
LaPAP, pET30 LrPAP, and pET30 MxPEP confirming successful construction of 
these vectors. 
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2.3.4 Expression and purification of PAPs and PEPs in E. coli strain BL21(DE3) 
The expression of each PEP and PAP in BL21(DE3) was analyzed via SDS-PAGE. LaPAP 
(38.13 kDa), MxPEP (79.83 kDa), and LrPAP (37.81 kDa) were purified at the expected 
sizes from the soluble cell lysate fractions (Figure 2-6A and Figure 2-6B). According to 
figure 2-6C, AnPat PAP (61.31 kDa) was not detected in any of the soluble samples; 
however, three bands (~55, 40, and 15 kDa) become more apparent in both insoluble 
samples (AnPat PAP 90 pellet and AnPat PAP 90 pellet purified). Additionally, a ~60 kDa 
band was further purified from the insoluble fraction of the induced samples (AnPat PAP 
90 pellet purified). The ~55, 40, and 15 kDa fragments from the purified AnPat PAP pellet 
were detected with Ni-HRP; however, the ~60 kDa fragment was not observed (Figure 2-
7). GFP (29.90 kDa) was used to control for the induction with IPTG and purification with 
Ni-NTA resin.  
 
 
 
 
 
 
 
 
Figure 2-6B. Lysates and Purified Samples of GFP and LrPAP. Samples were 
analyzed by SDS-PAGE (12%). The expected sizes for GFP and LrPAP were 29.90 
kDa and 37.81 kDa, respectively. The gel contains lysates, pellets, and purified 
samples that were not induced (0) and induced with IPTG for 90 minutes (90).  
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Figure 2-6A. Lysates and Purified Samples of GFP, LaPAP, and MxPEP. Samples 
were analyzed by SDS-PAGE (12%). The expected sizes for GFP, LaPAP, and MxPEP 
were 29.90 kDa, 38.13 kDa, and 79.83 kDa, respectively. The gel contains lysates and 
purified samples that were not induced (0) and induced with IPTG for 90 minutes (90).  
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Figure 2-6C. Pellets, Lysates, and Purified Samples of AnPat PAP. The expected sizes 
for GFP and AnPat PAP were 29.90 kDa and 61.31 kDa, respectively. SDS-PAGE 
contains pellets, lysates, and purified samples that were not induced (0) and induced with 
IPTG for 90 minutes (90). Both pellets from the induced samples contained three unique 
bands (~55, 40, and 15 kDa) that were not apparent in the other AnPat PAP samples (black 
arrows). Additionally, a ~60 kDa band was detected in the purified AnPat PAP 90 pellet 
(white arrow).                                                             
15 kDa 
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2.3.5 Enzyme activity 
AnPatPEP was not expressed as expected in BL21(DE3), therefore, only LaPAP, LrPAP, 
and MxPEP were further evaluated for cleavage activity. The protein concentrations of 
LaPAP, LrPAP, and MxPEP were determined to be 26.63 µM, 112.13 µM, and 21.65 µM, 
respectively.  
 
According to Beer’s law (A=Hbc), the absorbance of a sample is dependent on the 
concentration and molar absorptivity of the substance in question as well as the pathlength 
of light. Because a vertical beam of light was used in this assay, the pathlength was 
Figure 2-7. Western Blot of GFP and AnPat PEP. All samples were 
purified with Ni-NTA resin and probed with 1:500 Ni-HRP. As expected,  
GFP was detected 29.90 kDa. The ~55 and 40 kDa fragments (black arrows) 
were strongly detected, and the ~15 kDa fragment (gray arrow) was faintly 
detected from the AnPat PAP pellet.  
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dependent on the volume of the reaction. The absorbances of 200 µl volumes of diluted 
PNP samples yielded an average pathlength of 0.675 cm. From this pathlength, HpNA was 
calculated to be 13037.037 M-1 cm-1. This value was used to determine Vmax, Km, and kcat 
for LaPAP, LrPAP, and MxPEP (Table 2-4).  
 
In triplicate reactions that assessed the cleavage activity of LaPAP or LrPAP on H-Pro-
pNA, the Km values of LaPAP and LrPAP were calculated to be 0.501 mM (Figure 2-8A) 
and 0.625 mM (Figure 2-8B), respectively. LaPAP yielded a Vmax=1.43x10-5 IU and 
LrPAP exhibited Vmax= 6.49x10-5 IU. Neither LaPAP nor LrPAP exhibited cleavage 
activity on the Suc-Ala-Pro-pNA substrate (data not shown).  
 
In four replicate reactions containing MxPEP and Suc-Ala-Pro-pNA, MxPEP exhibited a 
Km=0.685 mM and Vmax=2.87x10-3 IU (Figure 2-8C). There was no cleavage activity from 
MxPEP on the H-Pro-pNA substrate (data not shown).  
 
 
 
 
 
 
Enzyme Vmax (IU) Km (mM) kcat (sec-1) kcat/Km (sec-1 mM-1) 
LaPAP 1.43x10-5 0.501 1.99x10-3 3.98x10-3 
LrPAP 6.49x10-5 0.625 1.80x10-2 2.88 x10-2 
MxPEP 2.87x10-3 0.685 15.937 23.26 
Table 2-4. Summary of the Kinetic Parameters (Vmax, Km, kcat, and kcat/Km) for 
LaPAP, LrPAP, and MxPEP.  
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Figure 2-8A. LaPAP Enzyme Kinetics with H-Pro-pNA. (a) Michaelis-Menten plot. 
(b) Lineweaver-Burk plot that yielded a linear regression line with a slope of 3.49x104 
and a y-intercept of 6.94x104. LaPAP exhibited Vmax= 1.43x10-5 IU and Km=0.501 mM. 
All values represent the mean r SD.   
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Figure 2-8B. LrPAP Enzyme Kinetics with H-Pro-pNA. (a) Michaelis-Menten 
plot. (b) Lineweaver-Burk plot that yielded a linear regression line with a slope of 
9.63x103 and a y-intercept of 1.52x104. LrPAP exhibited Vmax= 6.49x10-5 IU and 
Km=0.625 mM. All values represent mean r SD. 
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Figure 2-8C. MxPEP Enzyme Kinetics with Suc-Ala-Pro-pNA. (a) Michaelis-
Menten plot. (b) Lineweaver-Burk plot that yielded a linear regression line with a slope 
of 2.39x102 and a y-intercept of 3.49x102. MxPEP exhibited Vmax= 2.87x10-3 IU and 
Km=0.685 mM. Each value represents the mean r SD.  
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2.4 Discussion 
The AnPat PAP, MxPEP, and LrPAP sequences were successfully optimized for 
expression in E. coli and L. reuteri. Following optimization of these sequences, all pET30 
expression vectors were successfully cloned into BL21(DE3) (Figure 2-5), but only 
LaPAP, LrPAP, and MxPEP were expressed as soluble proteins that could be purified 
(Figure 2-6A and Figure 2-6B). Because all pET30 vectors contained a histidine tag at the 
C-terminus, the 3 AnPat PAP fragments (~55, 40, and 15 kDa) purified from the insoluble 
fraction of the cell lysate suggested that AnPat PAP was most likely cleaved at 3 possible 
sites on the N-terminus. Furthermore, these fragments were detected by western blot. 
Altogether, these data suggest that AnPat PAP may have been cleaved prior to protein 
purification. Cleavage that occurred post purification would result in noticeable N-terminal 
fragments on SDS-PAGE that were absent on the western blot. Moreover, a previous study 
reported a decrease in protein solubility with the introduction of synonymous codon 
substitutions (Cortazzo et al. 2002). It has been proposed that an increase in the rate of 
translation due the elimination of codon bias has an adverse effect on heterologous protein 
solubility (Rosano and Ceccarelli 2009). Although this may not be the definitive reason for 
the insoluble AnPat PAP fragments, alternate sequences of AnPat PAP should be 
considered if this enzyme is of interest for future use. Even though AnPat PAP was not 
successfully purified, these proteases would not be beneficial in the context of this study. 
AnPEP exhibits optimal activity at pH 2.5-4, but the duodenal pH ranges from 6-8 
(Tsiatsiani et al. 2017). Thus, AnPEP activity would be low in this area of the small 
intestine. However, the optimal pH environment for AnPEP along with the report that 
AnPEP is resistant to pepsin degradation make this enzyme suitable for activity in the 
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stomach (Kubota, Tanokura, and Takahashi 2005; Stepniak 2006). Therefore, AnPEP 
would be a promising candidate as an oral enzyme therapy since it could digest gluten in 
stomach before it entered the small intestine. AnPEP, marketed as Tolerase G ® by DSM, 
has been advertised as a dietary supplement that is active under gastric conditions to 
degrade the immunogenic epitopes of gluten (Salden et al. 2015). Because MxPEP, LaPAP, 
and LrPAP were successfully expressed as soluble proteins, the enzymatic activities of 
these proteases were evaluated to determine which would be incorporated into the L. 
reuteri expression cassette.  
 
The activities of LaPAP and LrPAP were assessed with H-Pro-pNA because PAPs are 
known to have terminal cleavage activity. This was supported when neither the LaPAP nor 
LrPAP exhibited cleavage activity with Suc-Ala-Pro-pNA (data not shown). Analysis on 
LaPAP and LrPAP revealed that these enzymes have a Km of 0.501 mM and 0.625 mM, 
respectively. Thus, these data suggest that LaPAP had a higher affinity for H-Pro-pNA than 
LrPAP. Because MxPEP acts upon internal proline residues, the activity of this enzyme 
was assessed with Suc-Ala-Pro-pNA. The MxPEP analyzed in this study had Km = 0.685 
mM; however, previous studies have shown MxPEP to have Km = 0.2-0.4 mM when used 
to cleave Suc-Ala-Pro-pNA (Shan et al. 2004; Shan, Mathews, and Khosla 2005; Kocadag 
Kocazorbaz and Zihnioglu 2017). Km values show that the MxPEP used in this study had 
a lower affinity towards Suc-AlaPro-pNA than the MxPEP used in the other studies. 
Moreover, the kcat/Km, indicator for catalytic efficiency, revealed a discrepancy from 
previous reports on MxPEP. In this study the kcat/Km for MxPEP was 23.26 sec-1 mM-1 
whereas Shan et al. and Kocazorbaz and Zihnioglu reported 97 and 20.33 sec-1 mM-1, 
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respectively (Shan et al. 2004; Kocadag Kocazorbaz and Zihnioglu 2017). Overall, the 
MxPEP characterized in this study showed sufficient cleavage activity against Suc-Ala-
Pro-pNA; however, it appeared to exhibit similar or lower effectiveness than previous 
investigations. Both aforementioned groups employed a C-terminal histidine tag to isolate 
MxPEP from whole cell lysates, therefore, the C-terminal histidine tag utilized in this study 
should not have any notable interference on MxPEP activity. It cannot be elucidated why 
there is a marked difference in catalytic efficiency of MxPEP between this study and Shan 
et al.. 
 
Although LrPAP, LaPAP, and MxPEP all cleaved their respective substrates, PEPs would 
be more effective than PAPs to cleave the immunogenic epitopes of gluten in the context 
of CD. The 33-mer (LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF) that bestows the 
immunogenic properties on gliadin contains a handful of internal proline residues that 
would not be accessible by a PAP. Thus, both LaPAP and LrPAP would be ineffective 
against this peptide as a whole. If the 33-mer was broken down into smaller components, 
then the PAPs might be able access any terminal prolines to further detoxify the epitopes. 
An enzyme such as MxPEP that can access the internal proline residues is more valuable 
to this study. Moreover, MxPEP was reported to exhibit optimal enzymatic activity at a pH 
of 7, thus it would be a strong candidate for gluten degradation in the duodenum which 
ranges from pH 6-8. Because MxPEP exhibited features of interest to this study, it was 
used in the construction of the L. reuteri expression cassette in pGKMCS.  
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3.0 Construction of a Vector-based Expression Cassette to Assess the Activity of 
MxPEP in Lactobacillus reuteri 
3.1 Introduction 
3.1.1 Probiotics as a delivery vehicle  
As mentioned in chapter 2, PEPs that cleave proline-containing oligopeptides may be 
effective in degrading the immunogenic epitopes of gluten to assuage the CD autoimmune 
response. Unfortunately, PEPs are notably absent from the gastrointestinal (GI) tract, 
therefore, a mechanism must be developed to introduce the enzymes into this environment. 
Orally administered enzymes are subjected to harsh conditions of the stomach, pancreatic 
juices, bile, and cleavage by brush border proteases that may render the enzymes inactive. 
An enzyme such as AnPEP would be valuable in the setting of the stomach since it 
maintains optimal activity at pH 2.5-4 and is resistant to pepsin degradation. As of 2015, 
the biotechnology company DSM launched Tolerase£ G, a commercially available dietary 
supplement of AnPEP advertised to break down residual gluten. One drawback is that 
Tolerase£ G must be consumed before each meal for the effects of the enzyme to take 
place. If an individual with CD forgets to administer the enzyme, then they are susceptible 
to the symptoms of accidental gluten exposure. Another mechanism of interest would be 
to maintain the PEP in duodenum, so an individual would not have to actively administer 
the enzyme prior to eating. PEPs delivered to the small intestine would need to be 
transported by a vehicle that can survive the environments of the GI tract and maintained 
at this site. Probiotic bacteria are well-suited for this function because they survive 
exposure to gastric acid in the stomach, colonize the small intestine, and are resistant to the 
bile salts and pancreatic juices that enter into the duodenum.  
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3.1.2 Applications of probiotics: food production and health benefits 
According to the Food and Agriculture Organization of the United Nations and the World 
Health Organization, probiotics are live microbial organisms that promote healthy 
digestion and influence the gut microbial community of a host when administered in 
sufficient quantities. These bacteria are endogenous to the human GI and urogenital tracts 
as well as the oral cavity; however, probiotics may also be supplemented through 
lyophilized forms (e.g. tablets and capsules) or foods (e.g. yogurt, sauerkraut, kimchi, etc.). 
These bacteria are often used to modify flavors and textures of food products, inhibit the 
growth of bacteria that lead to food spoilage, and protect against food-borne pathogens in 
humans. During the production of yogurt, probiotics produce various organic acids (e.g 
lactic acid, acetic acid, pyruvic acid) and volatile compounds (e.g. acetone, diacetyl, 
acetoin) that influence the overall flavor profile of yogurt. Nisin, an anti-microbial peptide 
produced by probiotic Lactococcus lactis, was licensed by the US Food and Drug 
Administration (USFDA) as a food additive for preservation and is commercially available 
under the name Nisaplin®. As an alternative to the use of antibiotics, probiotics have been 
used as feed additives to reduce infection of chickens and hens by Salmonella, thereby 
decreasing the risk of transmission of Salmonella through the human food supply chain. In 
addition to the contributions made within the food industry, supplementing probiotics into 
one’s diet may directly confer great health benefits to the host. 
 
There has been growing interest in the use of probiotics as orally delivered therapeutics for 
various GI disorders and health issues. In the murine gut, the presence of Lactobacillus 
reuteri corresponded to a reduction of fecal bacteria in the stomach when compared to that 
 47 
of a L. reuteri-free murine gut and a reduction in urease activity, a virulence factor that 
promotes the survival of pathogenic bacteria in the stomach (Wilson et al. 2014). Other 
studies have shown that probiotics may be beneficial as an adjunct treatment for enteric 
pathogens such as Helicobacter pylori, which is associated with the development of gastric 
ulcers. Some Lactobacilli probiotics may reduce the severity of an infection by impairing 
the capability of H. pylori to colonize the gastric mucosa (Ljungh and Wadström, 2006; de 
Klerk et al. 2016). These probiotics competitively adhere to the gastric epithelium or inhibit 
adhesion genes to impede H. pylori colonization. Moreover, Lactobacilli have also been 
shown to aid in the prevention of irritable bowel syndrome and the reduction of treatment-
related side effects such as antibiotic-associated diarrhea (Wilkins 2017). As described 
here, probiotics have intrinsically beneficial effects on a host, but these benefits may be 
further enhanced through genetic modification of the probiotics to express heterologous 
proteins. 
 
3.1.3 Benefits of heterologous protein expression in probiotics 
Lactic acid bacteria (LAB) such as Lactobacillus, Pediococcus, Streptococcus, 
Oenococcus, and Lactococcus are the most widely used probiotics. These bacteria are a 
group of Gram-positive, non-spore forming bacteria that primarily produce lactic acid from 
carbohydrate fermentation. Many LAB have been genetically engineered to express 
heterologous proteins for various applications. Recombinant Lactococcus lactis has been 
used to deliver ovalbumin (OVA), a protein found in egg whites, to the GI tract of OVA-
immunized mice and induced peripheral tolerance to OVA (Huibregtse et al. 2007). 
Another study reported that mice orally immunized with recombinant L. acidophilus 
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expressing Hp0410 (H. pylori adhesion protein) yielded an increase in Hp0410-specific 
IgG and IgA in the serum and intestinal mucosa, respectively (Hongying et al. 2014). These 
mice were further challenged with H. pylori and exhibited lower levels of colonization by 
the pathogen in the stomach. In another study, post-weaning Balb/c mice, an ideal animal 
model for studying lactose intolerance, were orally administered recombinant L. lactis 
expressing heterologous E-galactosidase and challenged with lactose (Li et al. 2012). The 
presence of the recombinant L. lactis strain alleviated symptoms, such as diarrhea, 
commonly associated with lactose intolerance in these mice. As can be seen from these 
studies, recombinant probiotics expressing heterologous proteins confer propitious effects 
on a host. These bacteria can be used as vaccines to deliver antigens or therapies to 
supplement the host with enzymes that alleviate disorder-related symptoms. In this study, 
we propose the use of the probiotic L. reuteri to deliver an enzyme therapy to assuage the 
immune response following accidental gluten exposure. 
 
3.1.4 The use of Lactobacillus reuteri as a therapy for CD 
 L. reuteri has been recognized as GRAS (generally regarded as safe) by the USFDA and 
is commonly used in the production of sourdough bread and other fermented cereals. This 
bacterium has been isolated from the GI tract of humans, pigs, rats, chickens, and guinea 
pigs (Hou et al. 2015). In humans, L. reuteri was found to colonize the stomach as well as 
the duodenum, jejunum, and ileum of the small intestine (Reuter 2001; Valeur et al. 2004). 
Because this bacterium is indigenous to the small intestine, L. reuteri commonly 
outcompete foreign probiotics, such as L. lactis, for colonization in the host (Walter, 
Britton, and Roos 2011). Strains of human L. reuteri are known to synthesize reuterin, a 
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unique broad-spectrum antimicrobial peptide produced during glycerol fermentation. 
Enteric pathogens (e.g., E. coli, Shigella, Salmonella, and Vibrio) and intestinal commensal 
bacteria (e.g. Bifidobacterium) have been shown to be susceptible to reuterin produced by 
L. reuteri (Park, Park, and Song 2008; Spinler et al. 2008). Thus, it has been hypothesized 
that the production of reuterin helps establish L. reuteri as a prominent member of small 
intestine microbiota. Moreover, L. reuteri has been shown to reverse a “leaky” gut by 
promoting the expression of tight junction proteins in lupus-prone mice (Mu et al. 2017). 
These characteristics of L. reuteri make it an ideal vehicle to deliver PEPs at the duodenum 
for the management of CD. 
 
Several strains of Lactobacilli encode functional PEPs (Degraeve et. al., 2003; Sanz et. al., 
2001; Rollan et. al., 2001; Xu et. al. 2001). Although L. reuteri expressed this peptidase 
activity and localizes to the site of pathogenesis, previous work in our lab revealed that it 
does not secrete the enzyme and only effectively digests the proline-containing substrates 
when lysed by sonication (Shurtleff 2009). As seen in chapter 2, MxPEP efficiently cleaved 
the chromogenic substrate Suc-Ala-Pro-pNA, and it is optimally active at a pH similar to 
that of the duodenum. Delivering MxPEP to the site of CD pathogenesis may be an 
effective therapy to assuage the immune response to gluten. The goal of this study was to 
genetically engineer L. reuteri to produce and secrete recombinant MxPEP. 
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3.1.5 Study Goal 
In this study, a vector-based expression system was employed for the production of 
recombinant proteins in L. reuteri. The system required a promoter and terminator that 
could be utilized by L. reuteri. Protein expression was driven by the following: the 
erythromycin ribosomal methylase gene (ermB) promoter derived from the broad-host 
vector pAMβ1 (Kim, Baek, and Pack 1991). This constitutive promoter was used 
successfully to drive recombinant protein expression in Lactobacillus spp. (Lizier et al. 
2010). The strong Rho-independent terminator from the r50 ribosomal L7/L12 gene (rplL) 
of E. coli was used to terminate transcription of the cassette (Morita et al. 2015). A signal 
sequence from the Bacillus licheniformis amylase gene (amyl) was incorporated into the 
cassette to generate a secreted form of the recombinant protein. This signal sequence was 
successfully used to secrete heterologous D-amylase in E. coli as well as L. reuteri (Malik 
et al. 2013; Wu et al. 2006). As seen in chapter 2, MxPEP was determined to be more 
effective than the LaPAP and LrPAP in the chromogenic substrate assay. Thus, MxPEP 
was incorporated into an expression cassette that was cloned into the L. reuteri expression 
vector, pGKMCS. The cassette contained the ermB promoter, amyl signal sequence, 
MxPEP, and rpIL terminator for the expression of a secreted form of MxPEP. Another 
variant of the expression cassette was constructed without the signal sequence to generate 
a cytosolic version of MxPEP. Additional vectors were constructed to produce cytosolic 
and secreted GFP as controls. After transformation into E. coli with the cytosolic versions 
of the vector, transformants exhibited stronger GFP fluorescence when the sequence was 
oriented in the opposite direction relative to the ermB promoter. It was hypothesized that 
lac promoter contained in the MCS was interfering with expression from the ermB 
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promoter. The lac promoter was removed from the expression vector; however, the absence 
of this promoter resulted in vector instability. 
 
3.2 Materials and Methods 
3.2.1 Strains, plasmids, and growth conditions 
E. coli strain MC1061 and L. reuteri strain 100-23C were utilized for this study. E. coli 
and L. reuteri cultures were grown in Luria Bertani (LB) and Man-Rogosa-Sharpe (MRS), 
respectively, broth or plates. To select for E. coli and L. reuteri containing pGKMCS-
derived vectors 250 µl/mg erythromycin (Erm 250) was added to LB and 5 µg/ml 
erythromycin (Erm 5) was added to MRS, respectively. 
 
3.2.2 Molecular techniques 
All molecular techniques were the same as in chapter 2.  
 
3.2.3 Digestion independent cloning 
Digestion independent cloning (DIC) reactions contained 1X Phusion master mix and a 3:1 
molar ratio of insert to vector (Figure 3-1). Thermocycling parameters for the DIC 
reactions were as follows: an initial denaturation at 98˚C for 10 second; 10 cycles of 98˚C 
for 1 second, 65˚C for 5 seconds, and 72˚C for 15 seconds per kb of product; and a final 
extension at 72˚C for 1 minute. The thermocycling parameters for the construction of the 
pGKMCS ermB fixed vectors were identical as previously stated; however, the annealing 
temperature of 65˚C was omitted.  
 
 52 
 
 
 
 
 
3.2.4 Construction of pGKMCS-derived vectors 
The pGKMCS vectors containing the Enterococcus faecalis erythromycin ribosomal 
methylase gene (ermB) promoter and the signal sequence from the Bacillus licheniformis 
α-amylase gene (amyl) were constructed as follows. According to figure 3-2, the ermB 
promoter containing a 5’ portion of the amyl signal sequence (Figure 3-2A) was amplified 
from a DNA string containing the ermB promoter as well as a Lactobacillus acidophilus 
lactate dehydrogenase gene (ldh) promoter, synthesized by Life Technologies (Carlsbad, 
CA, USA), with primers ErmB-AmyL-DIC-F/Erm-AmyL-DIC-R. An intermediate vector, 
pGKMCS 373 GFP Link, was used as a template to generate a DNA segment with the amyl 
signal sequence, GFP, his tag, and rplL terminator (Figure 3-2B) with the AmyL-F/rpIL-R 
primers. Subsequently, piece A and B were PCR stitched with the ErmB-AmyL-DIC 
Figure 3-1. Digestion Independent Cloning (DIC). The single stranded insert (A and 
B) anneal to complementary regions (A’ and B’) within the single stranded donor 
vector. The donor vector acts as a template to extend the 3’ end of the insert and form 
the double stranded target vector. 
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F/rpIL-R primers to create an amplicon containing the ermB promoter, amyl signal 
sequence, GFP, his tag, and rplL terminator (Figure3-2AB). DIC was used to clone piece 
AB into pGKMCS 373 GFP Link that was digested with EcoRI and AscI to create 
pGKMCS ermB amyl GFP. The reaction contained 1X Phusion master mix (Thermo 
Scientific, Rockford, IL, USA) and a 3:1 molar ratio of insert to vector. Thermocycling 
parameters for DIC were as follows: an initial denaturation at 98˚C for 10 seconds, 10 
cycles of 98˚C for 1 second, 65˚C for 5 seconds, and 72˚C for 23 seconds, and a final 
extension at 72˚C for 1 minute. pGKMCS ermB amyl GFP was digested with AscI to 
remove GFP and ligated with MxPEP digested with AscI to produce pGKMCS ermB amyl 
MxPEP. Table 3-1 contains the primers used to construct these vectors.  
 
In addition, pGKMCS vectors were created without the amyl signal sequence to produce a 
cytosolic version of the recombinant proteins. The ermB promoter was amplified from the 
ermB/ldhL DNA string with ErmB-AmyL-DIC-F/Erm-AscI-R. This generated an ermB 
promoter flanked by EcoRI on the 5’ end and AscI on the 3’ end. The amplified ermB 
promoter and pGKMCS ermB amyl GFP were digested with EcoRI and AscI, and these 
two fragments were ligated together to produce pGKMCS ermB. Subsequently, pGKMCS 
ermB and GFP or MxPEP were digested with AscI and ligated together to produce 
pGKMCS ermB GFP or pGKMCS ermB MxPEP.  
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Figure 3-2. Construction of pGKMCS ErmB AGFP. The ermB promoter and a 5’ end of 
the amyl signal sequence was amplified (A). An amplicon containing amyl signal sequence, 
GFP, histidine tag, and rplL terminator was generated from pGKMCS 373 GFP Link (B). 
Pieces A and B were PCR stitched to generate a ermB promoter, amyl signal sequence, GFP, 
his tag, and rplL terminator (AB). Following amplification, piece AB was incorporated into 
the vector via DIC. See text for details.   
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3.2.5 Construction of pGKMCS ermB fixed vectors 
After initial construction of the pGKMCS vectors, it was discovered that the ermB 
promoter was missing three nucleotides that led to a lack of protein expression in E. coli. 
These vectors were rebuilt to incorporate the three missing nucleotides to create a 
functional ermB promoter. The 5’ end of the ermB promoter was amplified with the ErmB-
AmyL-DIC-F/Erm-Fix-R primers (Fig. 3-3C). Using pGKMCS ermB GFP as a template, 
the 3’ end of the ermB promoter, GFP, his tag, and rplL terminator were amplified with the 
Erm-Fix-F/rplL-BI-R primers (Fig. 3-3D). The reaction was then treated with the 
restriction enzyme DpnI to remove pGKMCS ermB GFP from downstream reactions. 
Following the digest, piece C and D were PCR stitched with ErmB-AmyL-DIC F/rplL-BI-
R to generate a DNA sequence containing the fixed ermB promoter, GFP, histidine tag, 
and rplL terminator (Fig. 3-3CD). DIC was performed to create pGKMCS ermB fixed GFP. 
Thermocycling parameters were as follows: an initial denaturation at 98 ˚C for 10 seconds, 
10 cycles of 98 ˚C for 1 second and 72 ˚C for 23 seconds, and a final extension at 72 ˚C 
for 1 minute. For the construction of pGKMCS ermB fixed MxPEP, pGKMCS ermB fixed 
GFP was digested with AscI to remove GFP and MxPEP was cloned into the vector through 
ligation. Two additional vectors, pGKMCS ermB fixed amyl GFP and pGKMCS ermB 
fixed amyl MxPEP, were built to contain the amyl signal sequence. The procedure to create 
pGKMCS ermB fixed amyl GFP was identical to the construction of pGKMCS ermB fixed 
GFP; however, pGKMCS ermB amyl GFP was used as a template instead of pGKMCS 
ermB GFP. Table 3-1 contains the primers that were utilized in the construction of these 
fixed vectors. From here on any mention of a pGKMCS ermB vector will refer to these 
vectors with the three nucleotides added to the ermB promoter.  
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Figure 3-3. Construction of pGKMCS ErmB Fixed GFP Vector. The pGKMCS ermB fixed 
GFP vector contains 3 nucleotides in the ermB promoter that were omitted from the pGKMCS 
ermB GFP vector. The 5’ end of the ermB promter containing the 3 nucleotides was amplified 
from the ermB/ldh DNA string (C). The 3’ end of the ermB promoter, GFP, His tag, and rplL 
terminator were amplified from pGKMCS ermB GFP (D). Pieces C and D were stitched to 
generate an amplicon containing the fixed ermB promoter, GFP, his tag, and rplL terminator 
(CD). See text for details.  
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3.2.6 Construction of pGKMCS ermB Δ lac promoter vectors 
The lac promoter was included in the initial construction of the pGKMCS vector as part of 
the multiple cloning sequence (MCS) obtained from pCR2.1; however, it was removed 
from the pGKMCS-derived vectors in this study. The lac promoter was removed by 
amplifying pGKMCS ermB GFP with Del-Lac-Pro-BI-F and rplL-R. Amplification 
resulted in an amplicon flanked by BamHI sites on both the 5’ and 3’ ends. The amplicon 
was digested with BamHI and ligated to create pGKMCS ermB GFP Δ lac promoter. This 
process was repeated with pGKMCS ermB MxPEP and pGKMCS ermB  amyl MxPEP to 
construct these vectors without the lac promoter. 
 
3.2.7 Transformation of pGKMCS-derived vectors into E. coli 
All pGKMCS-derived vectors were first transformed into E. coli strain MC1061 to obtain 
purified plasmids for subsequent transformation into L. reuteri. The preparation of 
electrocompetent MC1061 cells was the same as in chapter 2.  
 
All electroporations were performed using the BTX Electro Cell Manipulator 600 (Harvard 
Apparatus Inc; 2.45 kV, 129 Ω, 25 µF). For each electroporation, 40 µl of cells transformed 
with 200 – 800 ng/µl pGKMCS-dervied vectors were incubated at 37˚C for 2 hour in 500 
µl SOC recovery medium supplemented with 100 ng/mL erythromycin. This sub-
inhibitory concentration of erythromycin was required to induce expression of the ermC 
promoter. After recovery incubation, 100 µl of cells were grown in LB Erm 250 broth and 
100 µl plated on LB Erm 250 agar and grown for 18 hours. For colony PCR (see materials 
 59 
and methods in chapter 2), 11-22 CFUs were evaluated to determine if the colonies 
contained the vector of interest. 
 
3.2.8 Assessing the stability of pGKMCS expression vectors  
Cultures of E. coli MC1061 carrying pGKMCS ermB GFP, pGKMCS ermB GFP Δ lac 
promoter, pGKMCS ermB MxPEP, pGKMCS ermB MxPEP Δ lac promoter, pGKMCS 
ermB amyl MxPEP and pGKMCS ermB amyl MxPEP Δ lac promoter were each grown 
overnight in 4 ml LB Erm 250 at 37 ˚C. Plasmids were isolated from 3 ml of each broth 
culture, and 10 µl of the remaining broth of each culture was inoculated into 4 ml LB Erm 
250 and grown overnight at 37˚C. This process was repeated for 5 consecutive days. All 
purified vectors (200 ng – 330 ng) were digested with XhoI and NcoI to analyze the stability 
of the vectors in E. coli.  
 
3.2.9 Plasmid sequencing 
The pGKMCS ermB GFP, pGKMCS ermB amyl GFP pGKMCS ermB GFP Δ lac 
promoter, pGKMCS ermB amyl MxPEP, and pGKMCS ermB amyl MxPEP Δ lac 
promoter were sequenced by GENEWIZ (South Plainfield, NJ, USA). Table 3-2 indicates 
which primers were used for each vector to obtain the sequence data. The MCS-R primer 
targeted the region upstream from the ermB promoter in all pGKMCS vectors whereas 
ErmB-AmyL-DIC-R annealed to the 3’ end of the ermB promoter. GFP-AscI-New-R and 
Mx-Opt-AscI-R bound to the 3’ end of GFP and MxPEP, respectively. Chromatograms 
were assessed with Sequencher (Gene Codes Corporation, Ann Arbor, MI, USA). 
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3.2.10 Transformation of pGKMCS-derived vectors into L. reuteri  
L. reuteri  was grown in 3 ml MRS overnight and the following day it was diluted 1:100 
in 10 ml MRS and grown at 37˚C in a candle jar until OD600 0.6. The culture was 
centrifuged at 4,000xg for 10 minutes at 4˚C and washed twice with ice-cold, sterile 
nanopure water. After washing the cells with water, the pellet was washed a final time in 
1/10 volume of EHRG buffer (1 mM HEPES, pH 7.0, 0.5 M raffinose, and 10% glycerol), 
resuspended in 1/100 volume of EHR buffer, stored in 100 µL aliquots, frozen in liquid  at 
– 80˚C.  
 
All electroporations into L. reuteri were performed using the BTX Electro Cell 
Manipulator 600 (Harvard Apparatus Inc; 1.5 kV, 480 Ω, 25 µF), and each 100 µL aliquot 
was transformed with 200 – 800 ng of plasmid DNA. Immediately after transformation, 
cells were recovered in 1 mL pre-warmed MRS containing 100 ng/mL erythromycin and 
incubated in a candle jar at 37˚C for 3 hours. After recovery, 250 µL of transformed cells 
Vector Forward 
Primer 
Reverse Primer 
pGKMCS ermB GFP MCS-R ErmB-AmyL-DIC-R 
pGKMCS ermB amyl GFP MCS-R GFP-AscI-New-R 
pGKMCS ermB GFP Δ lac promoter MCS-R ErmB-AmyL-DIC-R 
pGKMCS ermB amyl MxPEP MCS-R Mx-Opt-AscI-R 
Table 3-2. The pGKMCS Vectors and Associated Primers Used for Sequencing. 
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were inoculated 4 ml MRS Erm 5 broth and grown overnight at 37˚C in a candle jar for the 
enrichment of cells. The following day 3 ml of MRS Erm 5 was inoculated with 50 µL of 
enriched cells and grown overnight. Overnight cultures were streaked on MRS Erm 5 plates 
for the selection of colonies. To detect the presence of the transformed vector, 5-10 colonies 
were inoculated into 1 ml MRS Erm 5 and allowed to grow overnight. The following day 
100 µl aliquots were pelleted, a pipet tip was used to obtain a small portion of each pellet, 
and the cells were resuspended in separate aliquots from a PCR master mix (primers and 
1X GoTaq master mix).  
 
3.2.11 L. reuteri cell lysis and protein purification 
L. reuteri cultures harboring pGKMCS-derived vectors were grown overnight at 37˚C in 4 
ml MRS Erm 5 broth. Overnight cultures were diluted 1:50 in 10 ml MRS Erm 5 broth and 
grown to OD600= 0.5 – 0.7. After reaching log phase, cells were pelleted at 4,000xg for 10 
minutes at 4˚C. Pellets were washed twice in 1/10 volume of nanopure water and washed 
once in 1/100 volume TET buffer (20 mM Tris-HCl, pH 8.0, 2 mM EDTA, and 1.2% Triton 
X-100). After removing TET buffer, the pellets were resuspended in 1/10 volume lysozyme 
buffer (20 mM Tris-HCl, pH 8.0, 2 mM EDTA, and 1.2% Triton X-100) supplemented 
with 10 mg/ml lysozyme and 10 µg/ml mutanolysin. The cells were incubated at 37˚C for 
3 hours at 80 RPM. After the incubation period, samples were centrifuged at 4,000xg for 
10 minutes at 4˚C and the supernatant was discarded to remove the lysozyme and 
mutanolysin. The pellets were resuspended in 500 µl urea lysis buffer (20 mM KPO4, pH 
7.4, 8 M urea, and 0.5M NaCl) to lyse the cells. Samples were sonicated twice at ~14 RMS 
for 10 seconds to shear DNA molecules. Recombinant proteins containing a C-terminal 
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histidine tag were purified with HisPurTM Ni-NTA resin (Thermo Scientific, Rockford, IL, 
USA). Resin was prepared by washing twice with 500 µl nanopure water, once with 500 
µl urea lysis buffer, and resuspended in 300 µl urea lysis buffer. Lysates were incubated 
on ice with ~5 µl bed volume of Ni-NTA resin for 30 minutes. Ni-NTA bound proteins 
were separated from unbound proteins by centrifugation at 14,000xg for 1 minute at 4˚C, 
and the resin was washed twice with 500 µl urea lysis buffer.  
 
3.2.12 SDS-PAGE and western blot 
SDS-PAGE and western blot techniques were the same as in chapter 2.  
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3.3 Results  
3.3.1 Expression and purification of GFP and MxPEP in E. coli MC1061 
SDS-PAGE and western blots were used to analyze expression of GFP and MxPEP in E. 
coli MC1061 from pGKMCS ermB GFP and pGKMCS ermB MxPEP, respectively. GFP 
was not identified by SDS-PAGE; however, purified GFP (29.90 kDa) and a ~25 kDa band 
unique to the cell lysate appeared on the western blot when probed with anti-GFP 
conjugated to HRP (Figure3-4A). Because the pGKMCS expression vectors contained a 
C-terminal histidine tag, GFP may have been cleaved at the C-terminus prior to purification 
with Ni-NTA to generate the ~25 kDa band. MxPEP (79.83 kDa) expression was 
confirmed via SDS-PAGE and western blot using Ni-HRP (Figure 3-4B). As seen in from 
SDS-PAGE and western blot, MxPEP was purified as a soluble protein from the cell lysate. 
A similar sized band was detected by Ni-HRP in the MxPEP purified pellet indicating that 
some MxPEP was insoluble. Additionally, a ~35 kDa band was identified by Ni-HRP in 
both cell lysates of MxPEP. As seen with GFP, cleavage within MxPEP may have 
occurred. Evaluation of secreted GFP and MxPEP was not carried out in E. coli since the 
amyl signal peptide (SP) from B. licheniformis is used to export proteins in Gram positive 
bacteria. Although expression of cytosolic GFP and MxPEP was detected, E. coli harboring 
an intermediate pGKMCS GFP vector exhibited stronger GFP fluorescence with the 
reverse complement of the gene relative to the promoter of interest (data not shown). This 
observation led to a deeper investigation into the backbone of the pGKMCS vector. 
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Figure 3-4A. Lysates and Purified Samples of GFP from pGKMCS ErmB GFP. 
Samples were analyzed by 12% SDS-PAGE and western blot probed with anti-GFP 
conjugated to HRP. (a) GFP was not observed via SDS-PAGE (b) GFP was detected 
at the expected size (29.90 kDa) by western blot from the cell lysate purified with Ni-
NTA. An additional band ~25 kDa was detected by anti-GFP in the cell lysate. The 
pET30 GFP lane was used as a control for probing with anti-GFP. 
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Figure 3-4B. Lysates and Purified Samples of MxPEP from pGKMCS ErmB 
MxPEP. Samples were analyzed by 12 % SDS-PAGE and western blot probed with 
Ni-HRP. (a) MxPEP was purified from the cell lysate and appeared at the expected 
size of 79.83 kDa via SDS-PAGE. (b) Western blot analysis shows that MxPEP 
was detected from the purified pellet and cell lysates. Additionally, a ~35 kDa band 
was detected by Ni-HRP in the whole cell lysate as well as the purified cell lysate 
samples.  
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3.3.2 Assessing the stability of pGKMCS expression vectors 
It was discovered that the multiple cloning site of pGKMCS contained the lac promoter. 
In silico analysis revealed that the pGKMCS ermB expression vectors were constructed 
with the lac promoter located downstream and in the opposite orientation of the ermB 
promoter. Thus, the heightened GFP fluorescence that was associated with the reverse 
complement gene was likely due to expression from the lac promoter. We hypothesized 
that the lac promoter overpowered the ermB promoter and removed the lac promoter from 
the pGKMCS vectors in order to obtain unobstructed heterologous protein expression from 
L. reuteri.  
 
After the removal of the lac promoter, E. coli transformants were screened via diagnostic 
digest with XhoI and NcoI; however, inconsistent digestion patterns were observed among 
transformants that were confirmed by colony PCR (data not shown). This was seen most 
prominently with cells transformed with pGKMCS ermB amyl MxPEP ' LP (EAM ' LP). 
Due to these observations, the stability of all pGKMCS expression vectors was evaluated 
by subculturing and isolating vectors over a longer period of time (5-6 days). These vectors 
were assessed through diagnostic digests with XhoI and NcoI. According to figure 3-5A, 
all pGKMCS ermB GFP (EG) cultures consistently yielded the expected digest patterns 
(4,466, 750, and 594 bp). Similarly, all pGKMCS ermB GFP Δ lac promoter (EG ' LP) 
cultures produced the expected 4,308, 750, and 594 bp bands; however, a unique ~3,000 
bp band developed by the 3rd day of subculturing (EG ' LP rd 3-5).  
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All pGKMCS ermB MxPEP (EM) cultures maintained consistent but unexpected digest 
patterns (Figure 3-5B). The 4,466, 1,992, and 705 bp bands were expected; however, the 
~3,500 bp band was not anticipated for these XhoI and NcoI digests (EM rd 1-5). This 
~3,500 bp band may be attributed to the formation of covalently closed circular DNA 
which can form during alkaline lysis plasmid purification (Sayers, Evans, and Thomson 
1996). Contrastingly, only pGKMCS ermB MxPEP' lac promoter (EM ' LP) rd 1-3 
maintained the expected 4,308, 1,992, and 705 bp patterns. Subsequent digests revealed a 
loss of the 1,992 bp band and the introduction of a ~2,500 bp band (EM ' LP rd 4-5). 
Figure 3-5A. Molecular Evolution of pGKMCS EG and EG'LP. Digests were 
analyzed on 1% agarose gel. EG rd 1-5 (4,466, 750, and 594 bp) and EG ' LP rd 
1-5 (4,308, 750, and 594 bp) vectors display the expected band patterns; however, 
EG ' LP rd 3-5 produced a new band at ~3,000 bp.  
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As seen in figure 3-5C, all 5 restriction digests on pGKMCS ermB amyl MxPEP (EAM) 
consistently yielded the expected band sizes of 4,466, 2,107, and 705 bp (EAM rd 1-5); 
however, a faint ~3500 bp band first appeared on the 3rd day of subculturing (EAM rd 3-
5). The digest on pGKMCS ermB amyl MxPEP Δ lac promoter (EAM ' LP) culture 
yielded the expected fragment sizes of 4,308, 2,107, and 705 bp on the 1st – 4th days of 
growth (EAM Δ LP rd 1-4); however, the vectors obtained on the 2nd - 4th days of growth 
contained an additional band at ~3,000 bp (EAM Δ LP rd 2-4). A drastic change in the 
Figure 3-5B. Molecular Evolution of pGKMCS EM and EM'LP. Digests were 
analyzed on 1% agarose gel. All EM vectors produced the expected band patterns 
(4,466, 1,992, and 705 bp); however, an additional ~3,500 bp band resulted in all 
digests as well. EM ' LP rd 1-3 display the expected band patterns (4,308, 1,992, 
and 705 bp). In both EM ' LP rd 4-5 the 1,992 bp bands shifted to ~2,500 bp.  
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Figure 3-5C. Molecular Evolution of pGKMCS EAM and EAM'LP. Digests were 
analyzed on 1% agarose gel. All digests on EAM rd 1-5 consistently produced the 
expected band sizes (4,466, 2,107, and 705 bp), but a faint band at ~3,500 bp began to 
appear in EAM rd 3-5. The expected band patterns were produced in EAM ' LP rd 1-4 
(4,308, 2,107, and 705 bp); however, an unexpected band was observed at ~3,000 bp. The 
digest patterns for EAM rd 5 -6 did not yield any of the expected band sizes.   
band patterns occurred between the 4th and 5th days of growth. At the 5th and 6th days of 
growth the intensity of the ~3,000 bp band became more prominent, another unique band 
developed ~1,500 bp, the 705 bp band was lost, and inconsistent banding was seen at higher 
molecular weights (EAM Δ LP rd 5 and 6). Overall, these data indicate that there was 
selective pressure to alter the vectors without the lac promoter, but vectors with the lac 
promoter maintained stability over the course of 5 days. 
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Additionally, multiple attempts were conducted to isolate both pGKMCS EM ' LP and 
pGKMCS EAM ' LP from E. coli transformants, but there was a noticeable difference in 
the recovery frequencies between the two. Unaltered pGKMCS EM ' LP was frequently 
isolated from the transformants, but only one clone contained pGKMCS EAM ' LP that 
generated the expected band patterns (data not shown). Furthermore, mutations 
accumulated earlier in the cultures containing pGKMCS EAM ' LP compared to 
pGKMCS EM ' LP, and the mutations appeared to be more drastic in pGKMCS EAM ' 
LP (Figures 3-5B and 3-5C). 
 
3.3.3 Transformation and protein expression in L. reuteri 100-23C  
The pGKMCS vectors that yielded the appropriate digestion patterns with XhoI and NcoI 
were transformed into L. reuteri 100-23C. Successful transformation of the pGKMCS 
expression vectors in L. reuteri was confirmed through PCR. Table 3-3 contains the primer 
pairs that were used and the expected band sizes for each vector. The pGK-His-Link-
F/TS315-R primers were used to detect the absence or presence of the lac promoter. As 
seen in figure 3-6A, PCR on cultures harboring pGKMCS EG, EAG, EM, and EAM 
resulted in the expected band size of 270 bp indicating the presence of the lac promoter. 
Alternatively, those with pGKMCS EG Δ LP, EM Δ LP, and EAM Δ LP produced an 
amplicon at 112 bp to confirm the removal of the lac promoter. Vectors containing the 
ermB promoter and GFP were assessed with the ErmB-AmyL DIC-F/GFP-AscI-R primers. 
As expected, the cultures with pGKMCS EG and EG Δ LP produced an amplicon of 1299 
bp and EAG 1414 bp, respectively (Figure 3-6B). Additionally, amplification with these 
primers confirmed that GFP was correctly oriented in relation to the ermB promoter. The 
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vectors containing ermB with the MxPEP were not amplified, thereby indicating that these 
primers were specific to a vector containing GFP. A L. reuteri WT control was included in 
all colony PCRs to show that these primer pairs were specific to the vectors of interest. 
Lastly, transformation of vectors containing the ermB promoter and MxPEP were 
confirmed with the ErmB-Fix-F/Mx-Opt-AscI-R primers (Figure 3-6C). The PCR on the 
cultures with pGKMCS EM, EM Δ LP, EAM, and EAM Δ LP resulted in expected band 
sizes near ~2,700 bp; however no distinction could be made between vectors with (2768 
bp) or without (2653 bp) the amyl signal sequence. No amplification was observed when 
these primers were used with cultures containing GFP.  
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Vector pGK-His-link- F  
TS315-R 
ErmB-AmyL-DIC-F                           
GFP-AscI-R 
ErmB-Fix-F                          
Mx-Opt-AscI-R 
pGKMCS ermB GFP 
(EG) 
270 bp 1299 bp - 
pGKMCS ermB GFP Δ 
lac promoter (EGΔLP) 
112 bp 1299 bp - 
pGKMCS ermB amyl 
GFP (EAG) 
270 bp 1414 bp - 
pGKMCS ermB Mx 
(EM) 
270 bp - 2653 bp 
pGKMCS ermB Mx Δ lac 
promoter (EMΔLP) 
112 bp - 2653 bp 
pGKMCS ermB Mx amyl 
(EAM) 
270 bp - 2768 bp 
pGKMCS ermB amyl Mx 
Δ lac promoter 
(EAMΔLP) 
112 bp - 2768 bp 
Table 3-3. Expected Band Sizes for Each Vector and Set of Primers. Vectors amplified 
with pGK-His-Link-F/TS315-R verified the presence (270 bp) or absence (112 bp) of the 
lac promoter. Amplification with GFP-AscI-R or Mx-Opt-AscI-R confirmed the presence 
of GFP or MxPEP, respectively. 
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Figure 3-6A. L. reuteri Colony PCR to Confirm the Presence or Absence of the 
Lac Promoter in the pGKMCS Expression Vectors. As expected, vectors with 
the lac promoter yielded bands at 270 bp, and vectors without the lac promoter 
yielded bands at 112 bp. Dilutions (1:1000) of the EG and EGΔLP vectors were 
included as positive controls.  
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Figure 3-6B. L. reuteri Colony PCR to Confirm the Presence of ErmB, Amyl 
Signal Sequence, and GFP in pGKMCS Expression Vectors. As expected, vectors 
containing ermB and GFP resulted in a 1,299 bp band, and vectors with the amyl signal 
sequence yielded bands at 1,414 bp. Dilutions (1:1000) of the EG and EGΔLP vectors 
were included as positive controls.  
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Figure 3-6C. L. reuteri Colony PCR to Confirm the Presence of ErmB and 
MxPEP in pGKMCS Expression Vectors. As expected, vectors containing ermB 
and MxPEP resulted in a band ~2,700 bp. The vectors containing the amyl signal 
sequence (2,768 bp) cannot be distinguished from those without (2,653 bp) in this 
colony PCR. Dilutions (1:1000) of the EM and EAM vectors were included as positive 
controls.  
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After transformation into L. reuteri, expression of GFP and MxPEP was assessed by SDS-
PAGE. Whole cell lysates from L. reuteri with pGKMCS EG, EG ' LP, EM, or EM ' LP 
were incubated with Ni-NTA resin. Ni-NTA purified samples from E. coli BL21(DE3) 
pET30 GFP and pET30 MxPEP were included as positive controls. Both positive controls 
were detected at the appropriate sizes; however, GFP and MxPEP expression from L. 
reuteri was not detected (data not shown). Because cytosolic expression of GFP and 
MxPEP was not observed, L. reuteri cultures with pGKMCS EAM and EAM ' LP were 
not analyzed for secreted MxPEP.  
 
3.3.4 Sequencing of pGKMCS EG, pGKMCS EAG, pGKMCS EAM, and pGKMCS EG ' 
LP 
To determine if the lack of protein expression in L. reuteri was due to any mutations within 
the promoter region or coding region, pGKMCS EG, pGKMCS EAG, pGKMCS EAM, 
and pGKMCS EG ' LP were sequenced by GENEWIZ. All vectors sequenced with the 
MCS-R primer revealed that the ermB promoter was identical to the sequence from the 
Lizier et al. 2014. Moreover, pGKMCS EAG sequenced with GFP-AscI-New-R revealed 
that GFP did not contain any mutations. Samples sequenced with the ErmB-AmyL-SS-R 
and the Mx-opt-R primers did not generate viable sequences because these primers did not 
anneal to the vector of interest. Only 16 of the 45 nt in ErmB-AmyL-SS-R annealed to 
pGKMCS EG and pGKMCS EG ' LP. This region of the primer had a Tm=46.1˚C, thus 
the annealing temperature may have been too low allow for sufficient binding to the 
template. Because pGKMCS EM, EM ' LP, EAM, and EAM ' LP were constructed from 
the same MxPEP template, only pGKMCS EAM was used for sequencing. Three reverse 
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MxPEP primers were available for pGKMCS EAM (Mx-opt-R, Mx-opt-AI-R, and Mx-
opt-AI-R2). Of these three primers, Mx-opt-R does not bind to the 3’ end of MxPEP, 
therefore, the wrong reverse primer was used for sequencing.  
 
3.4 Discussion 
In this study an expression cassette containing the ermB promoter derived from E. faecalis 
was employed to drive expression of GFP and MxPEP, and the signal sequence from the 
B. licheniformis amyl gene was incorporated to generate secreted versions of these 
recombinant proteins in L. reuteri (Wu and Chung 2006; Lizier et al. 2010). Successful 
construction and transformation of these vectors into E. coli was confirmed through 
diagnostic digests and the  presence of cytosolic GFP and MxPEP. The same vectors were 
transformed into L. reuteri; however, cytosolic GFP and MxPEP were not detected. 
Because the L. reuteri cell lysates did not contain the heterologous proteins of interest, an 
analysis of secreted GFP and MxPEP was not performed. Although cytosolic GFP and 
MxPEP expression was confirmed in E. coli, stronger GFP fluorescence was observed 
when the reverse complement of GFP was inserted relative to the ermB promoter. This 
observation along with the absence of heterologous protein expression in L. reuteri led to 
a deeper investigation into the backbone of the pGKMCS vector.  
 
Previous work done in this lab cloned the multiple cloning site of pCR2.1 into a pGK12-
derived vector to construct pGKMCS. It was discovered that the pCR 2.1 multiple cloning 
site contained the lac promoter, and it was hypothesized that any expression from the ermB 
promoter was dulled due to the strength of the lac promoter. The lac promoter was removed 
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from all pGKMCS ermB expression vectors, but the absence this promoter had negative 
ramifications on the stability of the vectors. Initial positive clones for all pGKMCS ermB 
' LP vectors produced expected digest patterns with XhoI and NcoI; however, the patterns 
were altered after being subcultured for a total of 5 days. These results suggest that there 
may have been toxicity associated with the vectors without the lac promoter. E. coli 
MC1061 is RecA+, responsible for DNA repair and maintenance, which supports the notion 
that selective pressure provoked the accumulation of random mutations within these 
pGKMCS expression vectors. Cells containing the unaltered and potentially lethal variant 
of the vector do not survive. Contrastingly, cells with the mutated and benign vector may 
maintain erythromycin resistance, thereby becoming the dominant culture in the media.  
 
In addition to the overall toxicity associated with the removal of the lac promoter, 
pGKMCS ermB amyl MxPEP ' LP appeared to be more unstable than pGKMCS ermB 
MxPEP ' LP. The frequency of transformants that contained unaltered pGKMCS ermB 
amyl MxPEP ' LP was much lower than that of pGKMCS ermB MxPEP ' LP. 
Furthermore, mutations developed earlier over the course of 5 days within pGKMCS ermB 
amyl MxPEP ' LP than pGKMCS ermB MxPEP ' LP. These mutations resulted in a more 
drastic deviation from the original digestion pattern in pGKMCS ermB amyl MxPEP ' LP 
than pGKMCS ermB MxPEP ' LP. Altogether, these data further suggest that the presence 
of both the amyl signal sequence and MxPEP may have inflicted a higher degree of toxicity 
upon E. coli. However, it cannot be confirmed whether or not the amyl signal sequence 
made a significant contribution to the instability of the vectors. To assess the impact of the 
amyl signal sequence on the stability of the expression vectors, pGKMCS ermB amyl GFP 
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' LP must be constructed and the diagnostic digest experiment should be repeated. If the 
resulting data reveal more drastic mutations within pGKMCS ermB amyl GFP ' LP than 
pGKMCS ermB GFP ' LP, then it may indicate the amyl signal sequence amplifies the 
toxicity associated with these expression vectors. 
 
These data demonstrate the need for a tightly regulated promoter that would help alleviate 
the toxicity inflicted upon E. coli harboring these vectors. Thus, it is necessary to develop 
a controlled expression system to allow for stabilization of the expression vectors in both 
E. coli and L. reuteri and detection of MxPEP in L. reuteri. An inducible expression system 
of interest for L. reuteri is the nisin-controlled-gene expression (NICE) system derived 
from L. lactis. The NICE system, a two-component signal transduction system that relies 
on a histidine-protein kinase (nisK) and response regulator (nisR) to induce expression 
from the nisA promoter, is one of the most widely adapted and characterized for regulated 
gene expression in Gram positive bacteria. Expression of recombinant proteins from NICE 
is induced by subinhibitory concentrations of nisin, a broad-spectrum antimicrobial peptide 
that is widely used as a preservative in the food industry. This system was adapted in L. 
reuteri by integrating the nisA promoter, nisK, and nisR into the E. coli-L. reuteri shuttle 
vector pSTE32 to generate pNICE (Wu et al. 2006). It was reported that L. reuteri 
harboring pNICE successfully produced the heterologous D-amylase when induced with 
nisin, and induction resulted in a 6.9-fold increase of D-amylase compared to non-induced 
cultures. Since the NICE system is dependent on an antimicrobial compound for gene 
expression, pursuit of an alternative system may be of interest for inducible gene 
expression within the GI tract. Recent investigations have looked into the use of a bile-
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induced promoter for the expression of recombinant proteins in LAB. The bile-responsive 
lactate dehydrogenase (ldh) promoter from Lactobacillus johnsonii resulted in a 1.8-fold 
increase of recombinant E-galactosidase in Lactobacillus plantarum (Chae et al. 2019). In 
another study, the L. casei promoter P16090 was successfully induced by 0.05% bile salts 
and 0.025% cholic acid in L. reuteri to express an anaerobic fluorescent reporter gene 
(Martínez-Fernández et al. 2019). As an inhabitant of the duodenum of the small intestine, 
a bile-induced system may be of interest for recombinant gene expression in L. reuteri.  
 
Recombinant protein expression was not observed from L. reuteri, therefore, vectors that 
were transformed into L. reuteri were sequenced to determine if the ermB promoter, GFP, 
and MxPEP sequences were conserved. Sequence data revealed that the ermB promoter 
and GFP sequences did not contain any mutations. These data suggest that L. reuteri was 
transformed with the appropriate sequences for GFP expression.  It could not be determined 
if the MxPEP sequence was preserved because the wrong MxPEP primer was used for 
sequencing. Because the resulting ermB promoter sequence was identical to that of Lizier 
et al. 2014, expression of heterologous proteins from this promoter was possible. However, 
it could not be established if these vectors remained unchanged in L. reuteri because the 
resources required to isolate plasmids from Gram positive bacteria were not available. 
Moreover, L. reuteri 100-23 is also a RecA+ strain, therefore, it is possible that clones with 
the unaltered vector were selected against, and clones confirmed by colony PCR harbored 
the mutated version of the vector.  
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The absence of recombinant protein expression in L. reuteri may be further explained by 
the length of the spacer, the distance between the Shine-Dalgarno (S-D) sequence and start 
codon. It has been established that translation initiation is the most critical step in protein 
production (Chen et al. 1994; Berwal, Sreejith, and Pal 2010). When translation is initiated 
two parts of the ribosome, the 16s rRNA and P-site, interact with two sites on the mRNA, 
S-D sequence and start codon. Because these mRNA sites are related to the distance 
between the 3’ end of the 16s rRNA (complementary to the S-D sequence) and the P-site 
of the ribosome (holds the fMet-tRNA), the spacer has an impact on the efficiency of 
translation initiation. For example, protein expression in Bifidobacterium longum was 
evaluated with varying spacer lengths (4 nt to 9 nt), and it was reported that the loss of one 
nucleotide in the spacer (from 5 nt to 4 nt) resulted in 85% loss of protein expression (He, 
Sakaguchi, and Suzuki 2012). Additionally, previous studies have reported an average 
spacer length of 7-8 nt for endogenous genes, and a reduction in recombinant protein 
expression when the spacer ranged from 10-12 nt (Chen et al. 1994; Cao et al. 2015). The 
length of the spacer for all pGKMCS ermB expression vectors was 11 nt, therefore, it is 
plausible that this spacer was sufficient enough for expression in E. coli but not in L. 
reuteri. These 11 nt may have caused the distance to be too great for the 16s rRNA and 
fMet-tRNA to efficiently interact with the mRNA. Ultimately, expression may from the 
ermB promoter in both E. coli and L. reuteri may be enhanced if the length of the spacer 
was reduced to 7-8 nt. 
 
Furthermore, finding the right SP may prove to be a substantial challenge in the overall 
scope of this study. A previous study reported that it was essential for the signal sequence 
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to contain non-optimized codons to slow the rate of translation to allow the protein to fold 
correctly (Zalucki and Jennings 2007). Wu and Chung 2006 and Malik et al. 2013 both 
amplified the amyl signal sequence directly from the B. licheniformis ATCC 27811 
genome, but in this present study the sequence was optimized for expression L. reuteri. In 
the sequence sequenced used in this study, 37 of the 38 codons generated a relative 
adaptiveness value of 100% and the remaining codon had a value of 96%. Although it 
could not be determined in this study, it is possible that this optimized amyl signal sequence 
would not have successfully secreted recombinant proteins. If the D-amylase SP is of 
interest for the future of this study, then the original sequence from B. licheniformis ATCC 
27811 should be obtained. Another obstacle to SP selection may be a variation in 
translocation efficacy for different recombinant proteins. One study determined that the 
junction between the C-terminus of the SP and N-terminus of the heterologous protein 
influences translocation efficiency of the SP (Brockmeier et al. 2006). Another study 
further reported that SPs that worked well in Lactobacillus plantarum to secrete a 
staphylococcus nuclease did not have the same effect on a Lactobacillus amylovorus D-
amylase (Mathiesen et al. 2009). Thus, a SP that secretes GFP with great efficacy may not 
have the same effect on MxPEP. Ultimately, a SP-GFP fusion may not be of great interest 
for this study, and future researchers may only want to consider evaluating the efficiency 
of SPs with a N-terminal portion of MxPEP. Because a wide range of predicted SPs should 
be screened and evaluated with MxPEP, it is important that a robust L. reuteri expression 
cassette is developed to allow signal sequences to be easily swapped in and out of the 
vector. Additionally, an assay that is a cheap and time-saving alternative to purification of 
secreted MxPEP would be of great value to this study. For example, SPs that successfully 
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secrete D-amylase are identified by observing a zone of clearing on starch agar with the 
addition of Gram’s iodine. Transformants can be eliminated with ease if a zone of clearing 
is not observed. Once promising candidates are selected, a more thorough assessment of 
the SP secretion efficiency can be performed through purification of the recombinant 
protein from the culture medium. 
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APPENDICES 
A. Optimized Aspergillus niger Patent PAP (1581 bp) 
 
ATGCGTGCTTTTTCAGCTGTTGCTGCTGCTGCTTTAGCTTTATCATGGGCTTCA
TTAGCTCAAGCTGCTCGTCCACGTTTAGTTCCAAAACCAGTTTCACGTCCAGC
TTCATCAAAATCAGCTGCTACTACTGGTGAAGCTTATTTTGAACAATTATTAG
ATCATCATAATCCAGAAAAAGGTACTTTTTCACAACGTTATTGGTGGTCAACT
GAATATTGGGGTGGTCCAGGTTCACCAGTTGTTTTATTTACTCCAGGTGAAGT
TTCAGCTGATGGTTATGAAGGTTATTTAACTAATGGTACTTTAACTGGTGTTT
ATGCTCAAGAAATTCAAGGTGCTGTTATTTTAATTGAACATCGTTATTGGGGT
GATTCATCACCATATGAAGTTTTAAATGCTGAAACTTTACAATATTTAACTTT
AGATCAAGCTATTTTAGATATGACTTATTTTGCTGAAACTGTTAAATTACAAT
TTGATAATTCAACTCGTTCAAATGCTCAAAATGCTCCATGGGTTATGGTTGGT
GGTTCATATTCAGGTGCTTTAACTGCTTGGACTGAATCAGTTGCTCCAGGTAC
TTTTTGGGCTTATCATGCTACTTCAGCTCCAGTTGAAGCTATTTATGATTATTG
GCAATATTTTTATCCAATTCAACAAGGTATGGCTCAAAATTGTTCAAAAGATG
TTTCATTAGTTGCTGAATATGTTGATAAAATTGGTAAAAATGGTACTGCTAAA
GAACAACAAGCTTTAAAAGAATTATTTGGTTTAGGTGCTGTTGAACATTTTGA
TGATTTTGCTGCTGTTTTACCAAATGGTCCATATTTATGGCAAGATAATGATT
TTGCTACTGGTTATTCATCATTTTTTCAATTTTGTGATGCTGTTGAAGGTGTTG
AAGCTGGTGCTGCTGTTACTCCAGGTCCAGAAGGTGTTGGTTTAGAAAAAGC
TTTAGCTAATTATGCTAATTGGTTTAATTCAACTATTTTACCAGATTATTGTGC
TTCATATGGTTATTGGACTGATGAATGGTCAGTTGCTTGTTTTGATTCATATA
ATGCTTCATCACCAATTTATACTGATACTTCAGTTGGTAATGCTGTTGATCGT
CAATGGGAATGGTTTTTATGTAATGAACCATTTTTTTATTGGCAAGATGGTGC
TCCAGAAGGTACTTCAACTATTGTTCCACGTTTAGTTTCAGCTTCATATTGGC
AACGTCAATGTCCATTATATTTTCCAGAAACTAATGGTTATACTTATGGTTCA
GCTAAAGGTAAAAATGCTGCTACTGTTAATTCATGGACTGGTGGTTGGGATA
TGACTCGTAATACTACTCGTTTAATTTGGACTAATGGTCAATATGATCCATGG
CGTGATTCAGGTGTTTCATCAACTTTTCGTCCAGGTGGTCCATTAGCTTCAAC
TGCTAATGAACCAGTTCAAATTATTCCAGGTGGTTTTCATTGTTCAGATTTAT
ATATGGCTGATTATTATGCTAATGAAGGTGTTAAAAAAGTTGTTGATAATGA
AGTTAAACAAATTAAAGAATGGGTTGAAGAATATTATGCTTAA  
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B. Lactobacillus acidophilus PAP (918 bp) 
 
ATGAAAACTGGTACTAAAATTATCACTTTAGACAACGGTTACCACTTATGGA
CTAATACTCAAGGTGAAGGCGACATTCACTTATTAGCTCTTCACGGTGGTCCT
GGCGGCAACCACGAATATTGGGAAGACACTGCAGAACAACTAAAAAAACAA
GGCTTAGACGTCCAAGTTACCATGTACGATCAACTTGGCTCACTCTACTCAGA
TCAACCTGACTATTCTAATCCTGAAATTGCTAAAAAGTATTTAACTTATGAAT
ACTTCTTAGATGAAGTTGATGAAGTTCGTGAAAAGCTCGGTTTAGACAATATT
TACTTAATCGGTCAAAGTTGGGGTGGGTTATTAGTTCAAGAATACGCCGTTAA
ATATGGTCAGCACTTAAAGGGTGCGATCATTTCATCAATGGTTGATGAAATC
GACGAATATGTTGCATCAGTTAATCGTAGACGTCAAGAAGTTCTACCACAGA
CTGAAATTGATTTTATGCATGAATGTGAAAAGAACAATGATTACGACAACAA
ACGTTACCAAGATGACGTTCAAATCTTGAACATTAACTTTGTTGATCGTAAGC
AACCTTCAAAGCTTTACCATCTAAAGGACCTTGGTGGTTCTGCTGTTTACAAC
GCCTTCCAAGGTGATAATGAGTTTGTTATCACCGGTAAGTTAAAGGACTGGC
ACTTCAGAGATCAATTACACAAGATCAATGTTCCAACTTTGCTTACTTTTGGT
GAAAACGAAACTATGCCTATTTCAACTGCTAAGATTATGCAAAAGGAAATTC
CTAACTCACGTTTAGTTACTACTCCAGATGGTGGACACCACCACATGGTTGAT
AATCCTACAGTTTACTATAAACACTTGGCTGACTTCATTCGTGAAGTAGAAAA
CGGCACCTTTAAAGGCCAAAATTAA  
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C. Optimized Lactobacillus reuteri PAP (928 bp) 
 
aggcgcgccATGAAACAAGGCACTAAAATTATTACCCTTGATAATGGCTATCATC
TATGGACGAATACCCAAGGTGAAGGTGATATTCATTTATTGGCTTTGCATGGG
GGTCCTGGTGGCAATCATGAATACTGGGAAGACGCTGCTGAACAATTAAAGA
AGCAAGGTCTGAACGTTCAGGTAACAATGTATGATCAATTAGGTTCACTCTAT
TCTGATCAACCAGATTTTTCTGACCCTGAGATTGCGAAGAAGTACCTTACTTA
CGAATATTTCCTTGATGAAGTAGATGAAGTACGAGAAAAGCTTGGCTTAGAC
AATTTCTATCTTATCGGTCAAAGTTGGGGTGGCCTTTTAGTTCAAGAATACGC
TGTTAAGTATGGGCAACATCTTAAGGGCGCAATTATTTCTTCAATGGTTGACG
AAATTGATGAgTAcGTCGACcgtGTTAATGAATTAcgtGAAAAGACTCTTTCTCCA
GAAGCGGTTGCCTTTATGAAAGAATGCGAAGCCAAGAATGATTACAGTAATC
CTAAGTATCAAGAATGCGTTCAAGTAATGAATGAACAATACGTcGACcgtAAG
CAGCCATCCAAGCTTTATCATCTTAAAGACCTTGGTGGCACGGCGGTTTACAA
CGTATTCCAAGGTGATAACGAATTTGTGATTACCGGTAAGCTTAAAGACTGG
CATTTCCGTGACCAACTGAAGAACATTAAGGTGCCAACTTTAATTACATTTGG
TGAACACGAAACGATGCCAATCGAAACTGCTAAGACAATGAATAGTCTCATT
CCAAATTCACAGCTAGTTACTACTCCCGATGGTGGTCACCACCACATGGTAG
ATAACCCCGATGTTTATTACAAGCACCTCGCTGACTTTATTcgtAATGTTGAAA
ATAATACGTTTAATAATcggcgcgcct 
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D. Optimized Myxococcus xanthus PEP (2070 bp) 
 
ATGTCATATCCAGCTACTCGTGCTGAACAAGTTGTTGATACTTTACATGGTGT
TCAAGTTGCTGATCCATATCGTTGGTTAGAAGATGAAAAAGCTCCAGAAGTT
CAAACTTGGATGACTGCTCAAAATGCTCATGCTCGTGAAGCTTTAGCTAAATT
TCCAGGTCGTGAAGCTTTAGCTGCTCGTTTTAAAGAATTATTTTATACTGATT
CAGTTTCAACTCCATCACGTCGTAATGGTCGTTTTTTTTATGTTCGTACTCATA
AAGATAAAGAAAAAGCTATTTTATATTGGCGTCAAGGTGAATCAGGTCAAGA
AAAAGTTTTATTAGATCCAAATGGTTGGTCAAAAGATGGTACTGTTTCATTAG
GTACTTGGGCTGTTTCATGGGATGGTAAAAAAGTTGCTTTTGCTCAAAAACCA
AATGCTGCTGATGAAGCTGTTTTACATGTTATTGATGTTGATTCAGGTGAATG
GTCAAAAGTTGATGTTATTGAAGGTGGTAAATATGCTACTCCAAAATGGACT
CCAGATTCAAAAGGTTTTTATTATGAATGGTTACCAACTGATCCATCAATTAA
AGTTGATGAACGTCCAGGTTATACTACTATTCGTTATCATACTTTAGGTACTG
AACCATCAAAAGATACTGTTGTTCATGAACGTACTGGTGATCCAACTACTTTT
TTACAATCAGATTTATCACGTGATGGTAAATATTTATTTGTTTATATTTTACGT
GGTTGGTCAGAAAATGATGTTTATTGGAAACGTCCAGGTGAAAAAGATTTTC
GTTTATTAGTTAAAGGTGTTGGTGCTAAATATGAAGTTCATGCTTGGAAAGAT
CGTTTTTATGTTTTAACTGATGAAGGTGCTCCACGTCAACGTGTTTTTGAAGTT
GATCCAGCTAAACCAGCTCGTGCTTCATGGAAAGAAATTGTTCCAGAAGATT
CATCAGCTTCATTATTATCAGTTTCAATTGTTGGTGGTCATTTATCATTAGAAT
ATTTAAAAGATGCTACTTCAGAAGTTCGTGTTGCTACTTTAAAAGGTAAACCA
GTTCGTACTGTTCAATTACCAGGTGTTGGTGCTGCTTCAAATTTAATGGGTTT
AGAAGATTTAGATGATGCTTATTATGTTTTTACTTCATTTACTACTCCACGTCA
AATTTATAAAACTTCAGTTTCAACTGGTAAATCAGAATTATGGGCTAAAGTTG
ATGTTCCAATGAATCCAGAACAATATCAAGTTGAACAAGTTTTTTATGCTTCA
AAAGATGGTACTAAAGTTCCAATGTTTGTTGTTCATCGTAAAGATTTAAAACG
TGATGGTAATGCTCCAACTTTATTATATGGTTATGGTGGTTTTAATGTTAATAT
GGAAGCTAATTTTCGTTCATCAATTTTACCATGGTTAGATGCTGGTGGTGTTT
ATGCTGTTGCTAATTTACGTGGTGGTGGTGAATATGGTAAAGCTTGGCATGAT
GCTGGTCGTTTAGATAAAAAACAAAATGTTTTTGATGATTTTCATGCTGCTGC
TGAATATTTAGTTCAACAAAAATATACTCAACCAAAACGTTTAGCTATTTATG
GTGGTTCAAATGGTGGTTTATTAGTTGGTGCTGCTATGACTCAACGTCCAGAA
TTATATGGTGCTGTTGTTTGTGCTGTTCCATTATTAGATATGGTTCGTTATCAT
TTATTTGGTTCAGGTCGTACTTGGATTCCAGAATATGGTACTGCTGAAAAACC
AGAAGATTTTAAAACTTTACATGCTTATTCACCATATCATCATGTTCGTCCAG
ATGTTCGTTATCCAGCTTTATTAATGATGGCTGCTGATCATGATGATCGTGTT
GATCCAATGCATGCTCGTAAATTTGTTGCTGCTGTTCAAAATTCACCAGGTAA
TCCAGCTACTGCTTTATTACGTATTGAAGCTAATGCTGGTCATGGTGGTGCTG
ATCAAGTTGCTAAAGCTATTGAATCATCAGTTGATTTATATTCATTTTTATTTC
AAGTTTTAGATGTTCAAGGTGCTCAAGGTGGTGTTGCTGCTCAAGGTCGTTAA 
 
 
 
